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Autoantibodies and autoantigens
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Differential antibody recognition of the 349–364aa
B-cell epitope of human La/SSB protein and its
phosphorylated analogue
AG Terzoglou, JG Routsias, HM Moutsopoulos, AG Tzioufas
Department of Pathophysiology, School of Medicine, University of
Athens, Athens, Greece
Arthritis Res Ther 2004 6(Suppl 1):1 (DOI 10.1186/ar1043)
Background La/SSB is a phosphoprotein that associates with various
small RNA molecules. It has been found that the primary phosphorylation
site of the molecule during various physiological processes is in Ser366.
Objectives To determine whether the phosphorylation state of Ser366
could affect the antigenicity and the recognition of the protein by anti-
bodies from patients with primary Sjögren’s syndrome (pSS).
Methods Peptides 349–368aa and phos349–368aa (with the Ser366
residue phosphorylated) were synthesized. Sera with anti-La specificity
from 30 patients with pSS and sera from 19 normal individuals were
examined against the two synthetic peptides in ELISA. The antibody
specificity against the epitopes was tested with homologous and het-
erologous inhibition assays.
Results Of pSS sera 23% reacted against the 349–368aa peptide.
Sera binding to unphosphorylated peptide reacted also with
phos349–368aa. Although the same sera gave a positive reaction
against both peptides, the optical density values received from antibod-
ies to phos349–368aa were higher, indicating a higher concentration
or stronger affinity. When phos349–368aa was used as soluble
inhibitor, in homologous inhibition the reactivity was almost completely
abolished (92%). In contrast, when the unphosphorylated peptide was
used as inhibitor, the reactivity of sera against phos349–368aa was
only partially reduced (35%), indicating that sera from these patients
possess two distinct groups of antibodies: one against the unphospho-
rylated and one against the phosphorylated epitope.
Conclusion The phosphorylation of the serine366 residue resulted in a
significant increase in antibody binding on epitope 349–368aa of
La/SSB. These observations might explain the increased antigenicity of
La/SSB autoantigen in various pathological situations in which phos-
phorylation may occur.
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Surface-bound immune complexes containing
antibodies to collagen type II induce production of
TNF-α α, IL-1β β and IL-8 from monocytes via Fcγ γRII
M Mullazehi1, L Mathsson1, J Lampa2, J Rönnelid1,2
1Department of Clinical Immunology, Uppsala University, Uppsala,
Sweden; 2Department of Rheumatology, Karolinska Institute,
Stockholm, Sweden
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Background Antibodies to collagen type II (anti-CII) are found in a sub-
population of rheumatoid arthritis (RA) patients. In joint inflammation CII
epitopes are exposed to anti-CII, with possible formation of surface-
bound immune complexes (IC). We investigated whether surface-
bound CII anti-CII IC can induce cytokine production from mononuclear
cells and the mechanisms behind this.
Methods ELISA plates were coated with native human CII and blocked
with human serum albumin, after which sera with varying concentra-
tions of anti-CII were added. Serum-free mononuclear cell cultures
from healthy blood donors were then added, and after 20 hours
cytokine levels in supernatants were measured using ELISA. Parallel
wells without cell cultures were developed as anti-CII ELISAs. Sixty-five
RA patients and 10 control individuals were investigated cross-section-
ally, and 17 patients with anti-CII followed longitudinally for 1–5 years.
FcγRII and FcγRIII were blocked with specific antibodies. Cell deple-
tion/enrichment studies were performed to define responder cells.
High sensitivity CRP measurement was performed with nephelometry.
Results Surface-bound IC containing CII induce TNF-α, IL-1β and IL-8
from mononuclear cells via FcγRII. Cytokine production correlated highly
with anti-CII levels in the cross-sectional investigation. Five out of the six
longitudinally followed patients with highest anti-CII levels also showed
parallel changes in anti-CII OD, cytokine induction and CRP. Deple-
tion/enrichment studies showed monocytes to be the responding cells.
Conclusion Surface-bound anti-CII IC can form in inflamed joints. Such
IC can induce proinflammatory cytokines such as TNF-α, IL-1β and IL-8
from monocytes via FcγRII. Most serially followed patients with high anti-
CII levels showed parallel changes in anti-CII, induced cytokines and
CRP. This may imply mechanisms of pathophysiological importance in
the subpopulation of RA patients with high levels of anti-CII.
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Prothrombin fragment F1+2 in patients with
antiphospholipid antibodies
A Ambrozic, B Bozic, S Cucnik, T Kveder, B Rozman
University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
Arthritis Res Ther 2004 6(Suppl 1):3 (DOI 10.1186/ar1045)
Background Studies of specific markers for in vivo activation of coag-
ulation in patients with antiphospholipid antibodies (aPL) are very rare.
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Increased levels of prothrombin fragment F1+2 (F1+2) in patients with
APS were reported.
Objective Our aim was to ascertain the relationship of F1+2 plasma
levels with positive anticardiolipin (aCL) and anti-β2-glycoprotein I (anti-
β2-GPI, and to evaluate the effect of treatment on F1+2 values in
patients with APS.
Methods A total of 205 samples from 177 patients with suspected or
confirmed connective tissue disease without APS, and 15 samples
from nine patients with APS receiving anticoagulant (n = 8) or
antiplatelet (n = 1) therapy were tested for plasma F1+2 values (Enzyg-
nost F1+2 micro, Behring, Germany), aCL (IgG, IgM) and anti-β2-GPI
(IgG, IgM, IgA), all using in-house ELISAs.
Results Elevated values of F1+2 were statistically significantly associ-
ated with medium/high positive results for at least one isotype of aCL
(P = 0.027), anti-β2-GPI (P = 0.019) and aCL and/or anti-β2-GPI
(P = 0.014; Table 1). Furthermore, the mean level of F1+2 was signifi-
cantly higher in patients with medium/high aCL or anti-β2-GPI than in
those with negative/low positive aCL and anti-β2-GPI (P = 0.035). In all
15 plasma samples from APS patients, normal levels of F1+2 were
measured during treatment.
Conclusions Our study showed a significant association of aCL and
anti-β2-GPI with elevated levels of F1+2 in patients without APS not
receiving anticoagulant or antiaggregation therapy. aPL are believed to
be among the important causes of hypercoagulable state in those
patients. Furthermore, plasma values of F1+2 could be a very useful
indicator of successful treatment in APS patients.
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Concomitant appearance of anti-cardiolipin,
anti-β β2-glycoprotein I, anti-prothrombin and
anti-annexin V antibodies
S Cucnik, N Gaspersic, T Kveder, B Bozic
University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
Arthritis Res Ther 2004 6(Suppl 1):4 (DOI 10.1186/ar1046)
Background Anticardiolipin (aCL), anti-β2-glycoprotein I (anti-β2-GPI),
anti-prothrombin (aPT) and anti-annexin V (aANXV) antibodies are anti-
phospholipid antibodies (aPL) with different antigenic and diagnostic
specificities.
Objective To ascertain a simultaneous appearance of antigenically
undefined aCL and antigenically distinct anti-β2-GPI, aPT and aANXV.
Methods Sera from 92 patients (87 female, five male) were studied
(63 SLE, 19 sAPS [SLE with APS] and 10 pAPS). IgG, IgM and IgA
isotypes of aPL were determined using relevant ELISAs.
Results IgG was the most frequently detected isotype in all four ana-
lyzed aPL subtypes. According to diagnostic criteria, aCL were more
frequently found in patients with pAPS and sAPS than in those with
SLE. Similarly, aPT were more often elevated in patients with pAPS
(7/10) and sAPS (6/19) than in SLE (16/63; P < 0.05). The prevalence
of anti-β2-GPI and aANXV antibodies did not differ between patient
groups. Regardless of diagnosis, aPT were always detected in combi-
nation with aCL and/or anti-β2-GPI. aPT and aANXV were regularly
present in the sera positive also for aCL and/or anti-β2-GPI. aANXV
was detected as a single antibody in only one patient. In the pAPS
group concurrent multiple aPL varieties (three or four) were signifi-
cantly more frequently present than one or two types (8/10 versus
2/10; P < 0.05). Statistically significant associations of particular aPL
with clinical symptoms were as follows: elevated IgG anti-β2-GPI with
arterial thromboses, thrombocytopenia and foetal loss; IgG aPT with
arterial thromboses; and IgG aCL with venous thrombosis. IgA isotype
did not improve the clinical significance of the four analyzed aPL.
Conclusion In patients with SLE and/or APS, individual aPL were
found infrequently. Almost half of them had three or more aPL subsets
elevated at the same time.
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Antibodies against 25-mer synthetic peptide of M3
muscarinic acetylcholine receptor
P Zigon, A Hocevar, S Cucnik, B Bozic, B Rozman, M Tomsic, 
T Kveder
University Medical Centre, Ljubljana, Slovenia
Arthritis Res Ther 2004 6(Suppl 1):5 (DOI 10.1186/ar1047)
Background Antibodies against the M3 muscarinic acetylcholine
receptor (M3R) are believed to have inhibitory effects on parasympa-
thetic neurotransmission in patients with Sjögren’s syndrome (SJS),
leading to lacrimal and salivary glandular dysfunction. The second
extracellular loop domain of M3R is regarded as the ligand binding site.
Objectives The aim of our study was to optimize an ELISA for the
determination of antibodies against M3R synthetic peptide and to
analyze sera from patients with SJS, patients with systemic lupus ery-
thematosus (SLE) and healthy blood donors.
Methods The M3R 25-mer peptide (KRTVPPGECFIQFLSEPTITFG-
TAI) was synthesized (Diagen, Ljubjana, Slovenia) and used as the
antigen for anti-M3R ELISA. Synthetic peptide (10 mg/l) was used to
coat Costar medium binding plates; the detection system was alkaline
phosphatase/pNPP. Sera from 94 SJS patients (primary and sec-
ondary, age 17–77 years), 92 SLE patients (age 18–68 years) and
142 blood donors as controls (age 18–65 years) were tested.
Results: According to the cutoff value, estimated at the 95 percentile
of the controls (5/145 pos), positive values for anti-M3R were mea-
sured in 16/95 SJS and 8/92 SLE patients. Statistically significant dif-
ferences in anti-M3R was found in patients with SJS compared with
blood donors and compared with SLE patients (P = 0.0012 and
P = 0.047, respectively). There was no significant difference between
SLE patients and controls.
Conclusions This was the first study of anti-M3R antibodies using the
25-mer synthetic peptide as the antigen on large, well defined groups
of patients and blood donors, showing highly statistically significant
elevation in antibodies in primary and secondary SJS compared with
controls and SLE patients.
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Association of anti-ribosomal P protein antibodies
with neuropsychiatric systemic lupus erythematosus
A Ambrozic, B Bozic, B Rozman, B Lestan, T Kveder
University Medical Centre, Department of Rheumatology, Ljubljana, Slovenia
Arthritis Res Ther 2004 6(Suppl 1):6 (DOI 10.1186/ar1048)
Background There is an unclear association of anti-P with neuropsy-
chiatric (NP) SLE.
Objective Our objective was to determine the prevalence of anti-P in
150 SLE patients, focusing on psychosis and/or mood disorders, other
diffuse NP syndromes and focal NP syndromes, and to analyze the
manifestation of NP syndromes regarding SLE duration and anti-P
status.
Methods One hundred and fifty Caucasian SLE patients (133 female,
17 male) were studied, 88 of whom had a disease duration of more
than 5 years. IgG anti-P were detected by immunoblotting performed
on ribosomal extract of HeLa cells and/or by line immunoassay (INNO
LIA ANA). NP manifestations presenting at any time were defined
according to ACR case definitions for NP SLE. Patients in whom
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Table 1
Association of F1+2 with aCL and/or β2-GPI
Normal Elevated 
F1+2 F1+2 Total
aCL and β2-GPI negative/low positive 128 (81%) 31 (19%) 159
aCL and/or β2-GPI medium/high positive 29 (63%) 17 (37%) 46S3
diffuse and focal NP manifestations occurred at the same time were
classified according to the predominant manifestation.
Results Anti-P were positive in 17/150 (11.3%) patients. Diffuse NP
manifestations were diagnosed in 9/17 (53%) anti-P positive patients
(Table 1). Statistically significant associations of anti-P were found with
(1) psychosis and/or mood disorders (3/11, P < 0.05), (2) other diffuse
NP syndromes (6/14, P < 0.0001), and (3) all diffuse NP syndromes
(9/25;  P < 0.0001), as compared with patients without diffuse NP
manifestations (7/92). In the group of 88 patients with disease duration
greater than 5 years, an even stronger statistically significant associa-
tion of anti-P with diffuse NP manifestations was found.
Conclusion In our study anti-P antibodies showed a strong association
with diffuse but not focal NP syndromes in SLE patients, especially
those with disease duration over 5 years.
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Human cartilage glycoprotein 39-directed T cell
responses in health and arthritic diseases
JHM van Bilsen1, LR Lard1, EIH van der Voort1, D Elferink2, 
A Bakker1, H van Dongen1, AMM Miltenburg3, T Huizinga1, 
R de Vries2, REM Toes1
1Department of Rheumatology, Leiden University Medical Center,
Leiden, The Netherlands; 2Department of Immunohematology and
Blood Transfusion, Leiden University Medical Center, Leiden, The
Netherlands; 3Organon BV, Oss, The Netherlands
Arthritis Res Ther 2004 6(Suppl 1):7 (DOI 10.1186/ar1049)
Objective Although (self)antigen-directed T cells are thought to be key
mediators of many autoimmune diseases, a functionally distinct popula-
tion of CD4+ T cells – T regulatory cells (Treg cells) – dominantly inhibit
induction and progression of autoimmunity, as demonstrated in several
autoimmune models. In humans the presence of Treg cells has been
shown, but their role in autoimmune disease is not known. Likewise, no
(auto)antigens recognized by Treg cells have yet been identified at the
molecular level. The aim of these studies was to gain a better under-
standing of the identity of (auto)antigens recognized by Treg cells.
Results When analyzing the natural T cell response against a candi-
date autoantigen in rheumatoid arthritis (RA), namely human cartilage
gp-39 (HC gp-39), we found that healthy donors, although displaying a
typical Th1 reaction against a mixture of recall antigens, reacted
against HC gp-39 by producing IL-10. The IL-10 production was medi-
ated by CD4+ T cells. When HC gp-39-directed immunity of RA
patients was analyzed, a marked contrast was observed as Th1-like
reactivity was observed in a substantial number of patients as deter-
mined by the production of IFN-γ. More importantly, we found that HC
gp-39-directed immunity in healthy donors inhibits the T cell response
against a mixture of recall antigens. Likewise, HC gp-39-specific immu-
nity as well as HC gp-39-directed, IL-10-producing CD4+ T cell lines
were able to suppress MHC class I-restricted CTL reactivity.
Conclusion Together, these data point to a disease-associated bias in
the type of T cell response against HC gp-39, and identify HC gp-39
as a naturally occurring autoantigen that is recognized by Treg cells in
humans.
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Multiplex analysis of antinuclear antibodies by flow
cytometry using FIDIS
PJ Charles
Division of Immunology, Hammersmith Hospitals NHS Trust and
Kennedy Division, Imperial College, London, UK
Arthritis Res Ther 2004 6(Suppl 1):8 (DOI 10.1186/ar1050)
Background FIDIS (BMD, France) is a multiplex analytical flow cytome-
try system for the detection of antibodies. The aim of this study was to
evaluate the FIDIS connective assay system for the detection of antinu-
clear antibodies (ANA), and to assess the clinical utility of these para-
meters in the diagnosis of connective tissue diseases. The FIDIS
system simultaneously measures IgG antibodies directed at dsDNA,
Ro, La, RNP, Sm, Jo-1, Scl-70, rRNP, and CENP-B.
Methods Sera were obtained from 100 patients with SLE and
100 patients with Sjögren’s syndrome. A total of 78 sera from patients
with rheumatoid arthritis (RA) and 100 from normal healthy blood
donors were also tested.
Results Antibodies to Scl-70, Jo-1, and rRNP were not detected in any
of the sera from the disease groups. In the normal control group, the
only positive result obtained was in one sera that gave a weak positive
result for anti-CENP-B.
Conclusion The FIDIS connective assay system simultaneously mea-
sures IgG antibodies directed against nine different specificities. The
data presented indicate that this system provides an alternative strat-
egy for the measurement of specific ANA to the use of multiple single
analyte assays currently employed in many immunology laboratories.
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Short-lived plasmablasts and long-lived plasma cells
contribute to chronic humoral autoimmunity in
NZB/W mice
BF Hoyer1, K Moser1, AE Hauser1, A Peddinghaus1, C Voigt1, 
D Eilat2, A Radbruch1, RA Manz1, F Hiepe1
1Department of Medicine, Rheumatology and Clinical Immunology,
Charité University Hospital and German Rheumatism Research
Center, Berlin, Germany; 2Department of Medicine, Hadassah
University Hospital, Jerusalem, Israel
Arthritis Res Ther 2004 6(Suppl 1):9 (DOI 10.1186/ar1051)
The current view holds that chronic autoimmune diseases are driven by
the continuous activation of autoreactive B and T lymphocytes.
However, despite the use of potent immunosuppressive drugs
designed to interfere with this activation, the production of these
autoantibodies often persists and contributes to progression of the
immunopathology. In the present study, we analyzed the lifespan of
(auto)antibody-secreting cells (ASC) in the spleens of NZB/W mice, a
murine model of human systemic lupus erythematosus (SLE). The
number of splenic ASC increased in mice aged 1–5 months and
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Table 1
Study findings
Anti-P positive Anti-P negative
(n=17) (n=133)
1 Psychosis and/or mood disorders 3 (18%) 8 (6%)
2 Other diffuse NP syndromes 6 (35%) 8 (6%)
3 Only focal NP syndromes 1 (6%) 32 (24%)
4 Without NP manifestations 1 (41%) 85 (64%)
Table 1
Frequency of antibodies detected using FIDIS™
SLE SS RA
Anti-Ro 36 69 3.6
Anti-La 13 38 1.2
Anti-Sm 6 0 1.2
Anti-RNP/Sm 37 8 8
Anti-CENP-B 2 2 0
Anti-dsDNA 47 0 3.6S4
became stable thereafter. Less than 60% of the splenic antibody-
secreting cells were short-lived plasmablasts, whereas 40% were non-
dividing, long-lived plasma cells with a half-life of more than 6 months.
In NZB/W mice and D42 immunoglobulin heavy chain ‘knock-in’ mice,
we found that a fraction of DNA-specific plasma cells were also long-
lived. Although antiproliferative immunosuppressive therapy eliminates
short-lived plasmablasts, long-lived plasma cells can survive and con-
tinue to produce (auto)antibodies. Thus, long-lived, autoreactive plasma
cells are a relevant target for researchers aiming to develop curative
therapies for autoimmune diseases.
Acknowledgement Both senior authors (RAM and FH) contributed
equally to this work.
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Immune complexes from RA patients induce Fcγ γRII-
dependent and RF-correlated TNF-α α and IL-8
production from healthy PBMC
L Mathsson1, J Lampa2, M Mullazehi1, J Rönnelid1,2
1Department of Clinical Immunology, Uppsala University, Uppsala,
Sweden; 2Department of Rheumatology, Karolinska Institute,
Stockholm, Sweden
Arthritis Res Ther 2004 6(Suppl 1):10 (DOI 10.1186/ar1052)
Background Immune complexes (IC) induce production of cytokines
from mononuclear cells via Fcγ-receptors. We investigated whether
polyethylene glycol (PEG)-precipitated IC from serum and synovial fluid
(SF) from rheumatoid arthritis (RA) patients can induce production of
proinflammatory cytokines.
Methods In one study we compared sera and SF from 15 RA patients
and 15 healthy control sera. In a second study we used paired sera
and SF from 32 RA patients, 66% of which were rheumatoid factor
(RF) positive. The precipitates where diluted to the original volume in
PBS before 10% were added to serum-free PBMC cultures from two
healthy blood donors. After 20 hours TNF-α and IL-8 levels were mea-
sured using ELISA. In separate cell culture experiments FcγRII and
FcγRIII were blocked. RF in serum was determined by nephelometry
and IgG levels in precipitates were measured using ELISA.
Results We found a correlation between TNF-α induced by PEG pre-
cipitates from RA SF and RF levels in sera. Using the normal ELISA,
PEG precipitates were shown to contain some TNF-α but no IL-8,
using both whole and F(ab′)2 anti-TNF-α antibody ELISA systems.
TNF-α levels induced by SF precipitates, but not by serum precipitates,
correlated with number of swollen and tender joints at the time of sam-
pling. Blockade of FcγRII partly inhibited the TNF-α production in cul-
tures stimulated with precipitated IC, whereas blockade of FcγRIII did
not show any inhibitory effects.
Conclusion We showed a link between RF, PEG precipitated IgG
levels, and the induction of TNF-α and IL-8 from RA PEG precipitates.
The stimulation is partly mediated via FcγRII. As precipitate-induced
cytokine levels correlate with the number of affected joints, these find-
ings supports the hypothesis that IC and the correlated RF production
have a direct link to cytokine dependent inflammation in RA.
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Differential regulation of the expression of
chemokine receptor 3 and 4 during plasma cell
differentiation
G Muehlinghaus1, L Cigliano1, H Leyendeckers2, S Arce3, 
A Radbruch1, RA Manz1
1Deutsches Rheuma Forschungszentrum, Berlin, Germany; 2Miltenyi
Biotec, Bergisch Gladbach, Germany; 3Mucosal Immunity University
Buffalo, Buffalo, USA
Arthritis Res Ther 2004 6(Suppl 1):11 (DOI 10.1186/ar1053)
The duration of specific antibody titers ranges from a few weeks up to
several years. While the formation of antibody secreting plasma cells
takes place in secondary lymphoid tissues, long-lasting antibody
responses are provided by bone marrow plasma cells. The majority of
plasma cells initially formed remains in secondary lymphoid tissues and
die within a few days. Plasma cells that migrate into the bone marrow
or into chronically inflamed tissues can survive for much longer periods
of time. The capacity of plasma blasts to migrate into these tissues is
regulated by chemokine receptors. Expression of CXCR4 is important
for plasma cell migration into the bone marrow. CXCR3 ligands
expressed in large quantities in chronically inflamed tissues (e.g. in
effected kidneys in systemic lupus erythematosus) and can attract plas-
mablasts, thus mediating plasma cell accumulation at those sites. Here
we analyzed the regulation of chemokine receptor expression during
plasma cell differentiation in culture. Purified CXCR3-negative B cells
were activated T dependently in a two-step culture system, for 3 days
by CD40 ligand together with IL-2 and IL-10 and for 5 more days with
IL-2 and IL-10. Alternatively, cells were stimulated T independently with
CpG, IL-2 and IL-10. Addition of IFN-γ or monocyte/T-cell culture
supernatant in the initial culture, but not at late stages, induced the
expression of CXCR3 on plasma cells, thus suggesting that the regula-
tion of this receptor is an early event during plasma cell differentiation.
In contrast, CXCR4 was present on all plasma cells, formed under any
stimulation conditions and even when CXCR4-negative B cells were
activated to form plasma cells. These data indicate that expression of
CXCR4 and, as a consequence, the potential to migrate into the bone
marrow is generally associated with differentiation into plasma cells,
whereas the expression of CXCR3 must be induced by the inflamma-
tory cytokine IFN-γ.
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Two B cell populations differentially expressing IgVH
mRNAs in human RA synovium
S Ruzickova1, O Krystufkova1, L Sedova1, J Niederlova1, 
Z Cimburek2, T Dörner3, J Vencovsky1
1Institute of Rheumatology and LGE, Prague, Czech Republic;
2Department of Immunology and Gnotobiology, CAS, Prague, Czech
Republic; 3Department of Rheumatology, Charité, Berlin, Germany
Arthritis Res Ther 2004 6(Suppl 1):12 (DOI 10.1186/ar1054)
Background The lymphocytic infiltrates sometimes organized in
ectopic germinal centres in rheumatoid arthritis (RA) synovium contain
locally activated B cells expressing hypermutated immunoglobulin tran-
scripts and recombination-activating genes (Rag), suggesting an
ongoing antigen driven process directly in synovium.
Objective To test this hypothesis, mutational frequencies of
immunoglobulin mRNAs, signs of isotype switching and Rag gene
expression in individual RA synovial B cells were analyzed.
Methods Single-cell RT-PCR was used to analyze individual synovial
CD19+CD38+ and CD19+IgM+ B cells (as the reference population)
from two RA patients.
Results We found significantly reduced frequencies of peripheral
blood CD19+CD38+ B cells from RA patients as compared with con-
trols, suggesting their possible migration into the site of inflammation.
Three subsets of CD19+CD38+ B cells in RA synovium were detected,
expressing (1) only IgM transcripts (IgM+, 13.5%), (2) only IgG tran-
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scripts (IgG+, 48.7%), and (3) both IgM and IgG mRNAs (IgM+IgG+,
37.8%). The differences in mutational frequencies between them were
significant (Table 1). Over 40% of analyzed cells coexpressed Rag
mRNAs. Similar subsets and expression patterns were found in
CD19+IgM+ B cells; however, IgG+ cells displayed significantly
decreased mutational frequencies (3.6%; P < 0.0001). This might
reflect the presence of synovial B cell populations that differ in their
maturational status or biological function.
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Immunomics in inflammatory rheumatic diseases
Z Konthur1, K Adolph2, G Burguera1, A Sternjak1,2, A Förster2, 
H Lehrach1, GR Burmester2, K Skriner1,2
1Max-Planck-Institut für Molekulare Genetik, Berlin, Germany;
2Rheumatology & Clinical Immunology, Charité, Berlin, Germany
Arthritis Res Ther 2004 6(Suppl 1):13 (DOI 10.1186/ar1055)
Autoimmune diseases such as rheumatoid arthritis (RA) are character-
ized by autoantibodies to different autoantigenic proteins. Using pro-
teomic 2D immunoblots, we identified a new 40 kDa autoantigen –
hnRNP A3 – from HeLa nuclear extracts, which is frequently (30%)
detected by RA. Moreover, we used a set of protein arrays of about
50000 proteins derived from a human foetal brain cDNA expression
library for screening with patient sera. Additionally, we utilized a human
foetal brain cDNA library in a robot-based T7 phage display screening
system with RA patient sera. To determine the diversity of the enriched
library, we amplified the cDNA inserts and hybridized them onto the
custom-made human ENSEMBL cDNA array. By these methods, over
80 clones were identified to bind patient immunoglobulins. Moreover,
nine clones show only IgA-specific reactivity. We have now evaluated
two different clones thoroughly: the carboxyl-terminal half of the nucleo-
lar phosphoprotein p130 (NOPP 130) and a clone representing a
41-amino-acid mimetic peptide showing homology to calreticulin, a
previously reported autoantigen. The remaining proteins are still under-
going thorough investigation. Applying state-of-the-art proteomic tech-
niques, such as protein array and phage display, we have succeeded in
identifying more than 80 potentially autoantigenic marker molecules, of
which we have characterized a subset for RA specificity by screening
with large numbers of patient and control sera. However, none of the
molecules characterized thus far is exclusively discriminatory for RA
and they all exhibit overlap with other autoimmune diseases.
Autoantibodies: anticitrullin antibodies
14
VIDAS-EDRA fully automated testing of
autoantibodies to citrullinated proteins for the
diagnosis of rheumatoid arthritis
L Nogueira1, A Foussadier2, C Vincent1, C Clavel1, N Moinard1, 
M Jolivet2, G Serre1
1UMR 5165 CNRS-Toulouse III, Toulouse, France; 2Department of
Immunoassays, bioMérieux, Marcy l’Etoile, France
Arthritis Res Ther 2004 6(Suppl 1):14 (DOI 10.1186/ar1056)
Antiperinuclear factor and antikeratin antibodies (AKA) were shown to
belong to the same family of rheumatoid arthritis (RA)-specific autoanti-
bodies directed at ‘citrullinated’ peptidic epitopes borne by (pro)filag-
grins. We showed that their major target in the synovial tissue of RA
patients is deiminated (citrullinated) fibrin. Although (pro)filaggrins are
probably only cross-reactive proteins, their in vitro detection allowed
the development of several highly efficient tests for the diagnosis of
RA. Among those, the CCP ELISAs (CCP1 and CCP2), based on a
cyclic citrullinated peptide derived from human filaggrin, and the ArFA-
ELISA that we developed using a citrullinated recombinant rat filaggrin
appear to be the most promising. The rapidly growing interest of
rheumatologists in autoantibodies to citrullinated proteins rendered the
development of a convenient, fully automated test the next challenge.
Based on the ArFA-ELISA, we developed an automated test on the
VIDAS machine (bioMérieux), called VIDAS-EDRA (early diagnosis
rheumatoid arthritis). Thresholds were defined on a large series of
617 patients with well defined, established rheumatic diseases, includ-
ing 181 patients with RA. Antibodies to CCP1 and CCP2
(Immunoscan, Eurodiagnostica) were sought following the manufac-
turer procedures. Rheumatoid factor (RF) and AKA were also analyzed
in the series. The diagnostic performances of the tests were compared.
In established diseases the diagnostic sensitivity of the VIDAS-EDRA
was found to be identical to that of CCP2, and was significantly higher
than tests for AKA, CCP1 and RF.
Autoantibodies to citrullinated proteins can be efficiently detected with
the highly specific and sensitive automated test VIDAS-EDRA.
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Background Autoantibodies to citrullinated proteins (anti-CCP) can be
detected in up to 80% of rheumatoid arthritis (RA) patients with very
Available online http://arthritis-research.com/supplements/6/S1
Table 1
Mutational frequencies of IgVH mRNAs in RA synovial CD19+CD38+ and
CD19+IgM+ populations
CD19+CD38+ CD19+IgM+
IgM+ IgM+IgG+ IgG+ IgM+ IgM+IgG+ IgG+
Total of nt 1761 6617 4683 2128 2570 2079
Mutated nt 94 465 462 75 110 75
MF (%) 5.3 7.0 9.9 3.5 4.3 3.6
Table 1
Diagnostic sensitivity (%) computed at thresholds allowing 95.2% and
98.6% diagnostic specificity to be achieved
95.2% specificity 98.6% specificity
AKA 51.4 42.5
RF 56.4 16
CCP1 65.7 56.9
CCP2 74 63.5
VIDAS-EDRA 71.8 63.5S6
high specificity (98%). Citrulline residues, the target of the anti-CCP anti-
bodies, are formed by post-translational modification of arginine residues,
catalyzed by peptidylarginine deiminase enzymes (PAD; EC 3.5.3.15).
Objective Our aim was to investigate the full complexity of the family of
PAD enzymes and to locate putatively important conserved residues or
domains.
Methods We performed a thorough query for PAD sequences using
EST and genomic databases. With these data we constructed a com-
plete PAD alignment (ClustalW) and a phylogenetic tree (Treeview),
and mapped the different genes.
Results Next to the previously described PADs, we found several
(partial) novel sequences, both mammalian and nonmammalian. From
the alignment (available online at http://www.interscience.wiley.com/
jpages/0265-9247/suppmat/2003/25/v25.1106.html), it is clear that
the carboxyl-terminal half is more conserved than the amino-terminal
part. Some of the fully conserved residues (His475 and Cys655) have
been suggested to be important for catalytic activity of murine PAD2.
These residues would fit in the ‘catalytic pocket’, as has been
described for other arginine converting enzymes (arginine deiminases
EC 3.5.3.6. and amidinotransferases EC 2.1.4.1.). The negative charge
(on average –14) and low pI (about 5.8) of the enzyme are important
for its interactions with arginine substrates and with Ca2+ ions, which
are essential for PAD activity. A phylogenetic tree confirmed the human
PAD5 to be the orthologue of the murine PAD4. By comparing mRNA
and genomic sequences, the individual exons of all murine and human
PADs could be mapped in a tight conserved gene cluster (human chro-
mosome 1p36.1; mouse #4E1; rat #5q36). Structural characterization
of PADs will yield valuable clues regarding the aetiology of RA and for
the development of PAD inhibiting drugs.
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Background Rheumatoid factor (RF) is found in patients with systemic
lupus erythematosus (SLE). Anti-citrullinated peptide antibodies
(ACPA) are more specific for rheumatoid arthritis than RF.
Objective Our aim was to determine the prevalence of RF and ACPA
in SLE patients.
Methods In this study, samples from 201 consecutive patients diag-
nosed with SLE and fulfilling ACR criteria were used. Fine ANA reactiv-
ities were tested by INNO-LIA™ANA (Innogenetics, Gent, Belgium) and
by IIF on C. luciliae. RF was detected by latex fixation. ACPA were
detected by anti-CCP2 ELISA (Euro-Diagnostica, Arnhem, The Nether-
lands) and by a research INNO-LIA™RA (Innogenetics, Gent, Belgium)
for the detection of anti-pepA and anti-pepB antibodies. The preva-
lences of ACPA were compared by the McNemar test.
Results RF at a titre ≥160 was found in 26 patients (13.0%). ACPA
were found in 16 samples (Table 1). The prevalence of anti-CCP2 anti-
bodies was significantly higher than that of anti-pepA antibodies
(P = 0.001) and anti-pepB antibodies (P = 0.022).
Conclusion RF is found in 13.0% of SLE patients. Anti-CCP2 antibod-
ies are false-positive in 7.0% (n = 14) of SLE patients, which occurs
significantly more often than anti-pepA (1.5%, n = 3) and anti-pepB
(2.5%, n = 5) antibodies.
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serum markers for the diagnosis of rheumatoid
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Background Rheumatoid factor (RF) is the classical serum marker for
rheumatoid arthritis (RA). Anti-citrullinated peptide antibodies (ACPA)
have a higher sensitivity and specificity (spec) for RA.
Objective Our aim was to evaluate the diagnostic and predictive value
for RA of RF and antibodies to pepA and pepB (two synthetic sub-
strates for ACPA detection) in a setting relevant to routine clinical
practice.
Methods In this prospective multicentre study, samples were collected
at academic and nonacademic centres from 1003 consecutive patients
presenting for diagnostic work-up when the clinician included RA in the
differential diagnosis. RF was detected by latex fixation. A research
INNO-LIA™RA (Innogenetics, Belgium) was used to detect anti-pepA
and anti-pepB antibodies. Diagnoses were made by the clinician using
ACR criteria after 1 year follow-up. ROC curve analysis was used to
evaluate the diagnostic performance of the tests.
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Table 1
Characteristics of ACPA-positive SLE patients
Anti-CCP2
RF (U/ml;  cut-off  ANA  fine 
(titre) 25 U/ml) Anti-pepA Anti-pepB reactivities
1 1280 186 + + Ro60, SSB
2 0 28 – – SmB, SmD, histones, 
dsDNA
3 640 9 – + RNP-C
4 0 168 – – dsDNA
5 0 53 – – SmB, dsDNA
6 80 2 – + Histones, dsDNA
7 0 76 – – SmB, RNP-A, 
RNP-C, RiboP, 
histones
8 40 64 – – SmD, SmB, 
RNP-70k, 
RNP-C, RiboP
90 5 8 – – –
10 320 110 – – SmB, RNP-70k, 
RNP-A, RNP-C, 
Histones, dsDNA
11 0 28 – – –
12 0 36 – – –
13 320 78 + + SmB, RNP-70k, 
RNP-A, RNP-C
14 80 56 – – RNP-A, RiboP, 
Histones
15 640 52 – – RNP-70k, RNP-A
16 320 1600 + + Ro60S7
Results The following diagnoses were made: definite RA (n = 144),
non-RA (n = 629), undifferentiated (n = 156), and lost to follow up
(n = 74). The first two groups were used to determine sensitivity, speci-
ficity, and positive predictive value (PPV). ROC curve analysis (Fig. 1)
showed a higher area under the curve for RF than for anti-pepA and
anti-pepB antibodies (0.839 versus 0.784 and 0.788, respectively), but
in the high specificity region anti-pepA and anti-pepB antibodies per-
formed better than RF (Table 1).
Conclusion When high specificity is required, anti-pepA and anti-pepB
antibodies have a markedly higher sensitivity than RF. The highest PPV
are found when ACPA are very high.
18
Citrullinated proteins in arthritis: presence in joints
and effects on immunogenicity
K Lundberg1, S Nijenhuis2, E Vossenaar2, L Klareskog1, 
WJ van Venrooij2, H Erlandsson Harris1
1Department of Medicine, Karolinska Institutet, Stockholm, Sweden;
2Department of Biochemistry, University of Nijmegen, Nijmegen, The
Netherlands
Arthritis Res Ther 2004 6(Suppl 1):18 (DOI 10.1186/ar1060)
Background Autoantibodies (Ab) directed against citrulline (Cit)-con-
taining proteins have a specificity of nearly 100% in rheumatoid arthritis
(RA) patients. The presence of these markers early in disease, even
before clinical onset, and the observation that these autoantibodies are
produced locally in the pannus suggest an involvement in the patho-
genesis. The targeted epitopes are generated by deimination, a post-
translational modification catalyzed by the enzyme peptidyl arginine
deiminase.
Objective Our aim was to analyze the presence of Cit-proteins and fib-
rinogen in the joints at different time points in collagen-induced arthritis
(CIA) in rats and to investigate how citrullination of an autoantigen
affects its immunogenicity.
Methods Synovial tissue sections from DA rats were stained for
expression of citrulline and fibrinogen. Lew1AV1 rats were immunized
with Cit-rat serum albumin (RSA) or unmodified RSA, and antibody and
T-cell responses were evaluated.
Results Citrulline was detected in arthritic joints from disease onset
and increased expression was noted as disease progressed into a
more chronic state. Naïve rats or time points before arthritis onset were
negative for citrulline-specific staining. Infiltrating cells, as well as the
cartilage surface, stained positive for citrulline, although the major
source of citrullinated proteins appeared to be fibrin depositions. A
specific Cit-RSA T-cell response was observed in animals challenged
by Cit-RSA. In contrast, no response was recorded when RSA was
used as a stimulus. The IgG response revealed not only a response
toward the modified protein but also cross-reactivity to the unmodified
form of RSA.
Conclusion In CIA, joint inflammation precedes the presence of Cit-
proteins and citrullination increases immunogenicity of an autoantigen.
Our results suggest that citrullination is induced by inflammation and
might be contributing to the development of autoreactive T and B cells.
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peptides
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Background Antifilaggrin antibodies are highly specific serological
markers of rheumatoid arthritis (RA). They have been shown to com-
prise a heterogeneous population of antibodies directed at citrullinated
peptides. Recent studies suggest that the site of the initial antigenic
trigger where these autoantibodies are produced can be localized to
the synovial tissue.
Objective The aim of this study was to compare the recognition pat-
terns of antibodies in paired serum and synovial fluid samples of RA
patients toward citrullinated peptide sequences to investigate whether
or not they comprise the same antibody population.
Methods Arginine-rich peptide sequence corresponding to human pro-
filaggrin (amino acid residues 306–324) and sequences with citrulline
substitution at different positions were synthesized by mutipin peptide
synthesis on solid support. Completely citrullinated variant of the
19-mer peptide and shortened sequences were also produced. The
reactivity of these peptides with paired sera and synovial fluid samples
of RA patients were determined (n = 25). Results were evaluated sta-
tistically using the paired t test.
Results and Conclusion The results (Table 1) show that the
12–19 amino acid long epitopes are recognized by homogeneous anti-
body population present in serum and synovial fluid, whereas the reac-
tivities toward short citrullinated sequences differs significantly.
Acknowledgement This work was supported by the Hungarian grant:
OTKA T037876.
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ROC curves.
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Table 1
Diagnostic performance of serum markers using different cut offs
Antibody Cutoff Sensitivity (%) Specificity (%) PPV (%)
PepA Low 63.6 90.6 60.7
PepB 64.3 90.0 59.0
RF 69.2 90.1 61.5
PepA Intermediate 62.9 95.1 74.4
PepB 61.5 95.1 73.3
RF 55.2 94.6 69.9
PepA High 58.7 98.1 87.5
PepB 48.3 98.1 85.2
RF 42.0 97.8 81.1
PepA Very high 41.3 99.0 90.8
PepB 37.1 99.0 89.8
RF 21.0 99.0 83.3S8
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The presence of deiminated fibrin in the synovial
membrane is not specific for rheumatoid arthritis
S Chapuy-Regaud1, M Sebbag1, D Baeten2, C Clavel1, 
F De Keyser2, G Serre1
1UMR 5165 CNRS-Toulouse III, France; 2Department of
Rheumatology, University Hospital, Ghent, Belgium
Arthritis Res Ther 2004 6(Suppl 1):20 (DOI 10.1186/ar1062)
Background Autoantibodies to deiminated (citrullinated) forms of the
α and β chains of fibrin (AhFibA), also known as antifilaggrin autoanti-
bodies (AFA), are the most specific serological markers of rheumatoid
arthritis (RA). Deimination is critical in generating the AhFibA epitopes
and, in the synovial tissue (ST), deiminated fibrin is their major antigenic
target. Existence of fibrin deimination specifically in RA patients could
explain why the AhFibA response is RA specific.
Methods and Results To explore such an association, the presence of
deiminated fibrin in the ST was assessed in a series of 32 patients, 13
with RA and 19 with non-RA rheumatological disorders (controls). ST
biopsies were collected in macroscopically inflamed areas identified
under needle arthroscopy of the knee. Histopathological examination
confirmed the existence of synovitis in all of the samples. The presence
of deiminated fibrin was first assessed by immunoblotting of ST
extracts using antibodies to citrullyl residues and to the α and β chains
of fibrin, and AhFibA purified from a pool of RA sera. Deiminated fibrin
was evidenced in all of the ST samples. Moreover, variations in the ratio
of deiminated to total fibrin were not related to diagnosis. Immunohisto-
chemical analysis, performed on adjacent synovial biopsy sections of
19 of the 32 patients, using antibodies to the β chain of fibrin and to
citrullyl residues, allowed us to confirm the results obtained by
immunoblotting, because deiminated fibrin was detected in six RA
patients and six controls.
Conclusion Our results show the presence of deiminated fibrin in the
ST is not specific for RA and suggest that it is induced by ST inflam-
mation. Moreover, they show the production of AhFibA is not a direct
consequence of the presence of deiminated fibrin in the ST. Nonethe-
less, AhFibA are tightly associated with RA. Because they are also
present very early in the disease course, linked to disease severity and
produced in the ST, they probably play an important role in RA patho-
physiology.
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Background Antibodies directed at the Sa antigen are highly specific
for rheumatoid arthritis (RA) and can be detected in approximately 40%
of RA sera. The antigen, a doublet of protein bands of about 50 kDa, is
present in placenta and in RA synovial tissue. Although it has been
suggested that the Sa antigen is identical to citrullinated vimentin,
experimental proof for this has never been published.
Objective In this study we investigated the precise nature of the Sa antigen.
Methods Freshly purified Sa antigen from placenta was analyzed by
mass spectrometry. Immunoprecipitation and Western blot studies
were performed with anti-Sa patient sera, anti-vimentin antibodies and
antibodies specifically recognizing citrullinated proteins.
Results and Conclusion Peptide sequences that were obtained from
highly purified Sa antigen were unique to vimentin. Recombinant
vimentin, however, was not recognized by anti-Sa reference sera. In
vivo, vimentin is subjected to various post-translational modifications,
including citrullination. Because antibodies to citrullinated proteins are
known to be highly specific for RA, it was investigated whether Sa was
citrullinated. Our data show that Sa indeed is citrullinated vimentin.
Anti-Sa antibodies thus belong to the growing family of anti-citrullinated
protein antibodies, which also includes the well described anti-filaggrin
and anti-CCP antibodies. The presence of the Sa antigen in RA syn-
ovial tissue, the observations that vimentin is citrullinated in dying
human macrophages and that citrullinated vimentin peptides are prefer-
entially presented by HLA-DR4/shared epitope, make Sa a unique
autoantigen in RA. Studies on Sa may provide new insights on the
potential role of citrullinated synovial antigens and the antibodies
directed at them in the pathophysiology of RA.
Cytokines and chemokines
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Elevated expression of IL-18 in Sjögren’s syndrome:
distinct expression patterns of the active and
proactive forms
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Background IL-18 is an important immunoregulatory and proinflamma-
tory cytokine that is produced by various cell types, including antigen-
presenting cells and epithelial cells. IL-18 is synthesized as a
biologically inactive precursor molecule (proactive IL-18) that converts
into an active, mature molecule after enzymatic cleavage. Upregulated
levels of IL-18 have been identified in several autoimmune diseases,
but its role in Sjögren’s syndrome (SS) is uncertain.
Objective The aim of the study was to investigate the role of IL-18 in SS.
Methods RT-PCR analysis, immunohistochemistry and immunoblotting
(with distinct anti-IL-18 antibodies against the proactive and active
forms) were applied for the detection of IL-18 in cultured SG epithelial
cell (SGEC) lines established from patients with SS (n = 5) and from
non-SS disease control patients (n = 5), as well as in minor SG biopsy
specimens obtained from patients with primary SS (n = 12), secondary
SS (n = 5) and non-SS disease controls (n = 7) were used.
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Table 1
Comparison of the reactivities of antibodies in paired serum and
synovial fluid samples
Sequence P value Sequence P value
SHQESTXGXSXGXSGXSGS 0.754 TXGRSRGRSGRSG 0.598
SHQESTXGXSXGXSGRSGS 0.382 TXGRSRGRSGRS 0.129
SHQESTXGXSXGRSGRSGS 0.09 TXGRSRGRSGR 0.04*
SHQESTRGXSXGXSGXSGS 0.081 TXGRSRGRSG 0.122
SHQESTRGRSXGXSGXSGS 0.143 TXGRSRGRS 0.128
SHQESTRGRSRGXSGXSGS 0.192 TXGRSRGR 0.039*
TXGRSRG 0.019*
TXGRSR 0.003*
TXGRS 0.003*
TXGR 0.011*
*Significant difference. X, citrulline.S9
Results The expression of IL-18 mRNA was detected in all SGEC lines
tested. In addition, cultured SGEC express constitutively the proactive,
but not the mature, form of IL-18 protein, as demonstrated by
immunoblotting. In minor SG biopsies, strong expression of the IL-18
proactive protein was detected in the ductal epithelial and CD68+ infil-
trating macrophages of the SS patients, but not in the controls. The
expression of the active form of IL-18 was detected only in SS patients
and mainly in those with extended inflammatory lesions. In these
samples, active IL-18-positive cells were observed exclusively among
the CD68+ macrophages of the mononuclear cell infiltrates.
Conclusion Our data possibly indicate the role of IL-18 in the expan-
sion of lymphoepithelial lesions of SS patients. SGEC were found to
express only the proactive form of IL-18, the biological significance of
which remains to be determined.
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Background In the NZB/W murine model of lupus, various studies
have analyzed cytokine production during disease development with
contradictory results.
Objective The aim of this study was to analyze cytokine pattern of
splenic T cells from NZB/W mice. We assessed the possibility that a
shift in cytokine production is associated with age, disease activity, or
manifestation of nephritis.
Methods NZB/W mice of different ages spanning 5–36 weeks were
analyzed, and healthy (BALB/c × NZW) F1 mice were used as controls.
Proteinuria was measured using albustix. Plasma creatinine and autoan-
tibody levels were detected by commercial test kid and by ELISA,
respectively. Splenic CD4+ T cells stimulated with PMA/Ionomycin were
analyzed for intracellular cytokine staining by FACS analysis.
Results The increased frequency of IFN-γ producing CD4+ T cells corre-
lated with age, anti-dsDNA IgG antibody levels and proteinuria. The
increasing number of IL-10 producers was only associated with anti-
dsDNA antibody levels and proteinuria. A small gain in IL-4+ T cells corre-
lated with plasma creatinine. Neither the number of IL-10 nor that of IL-4
exhibiting T cells correlated with age. There was no significant change
observed in the production of TNF-α. Calculating the IFN-γ/IL-4 ratio, an
increasing shift toward a Th1 response was observed. The shift strongly
correlated with anti-dsDNA antibody titres and proteinuria. In contrast, no
cytokine shift could be observed in control mice with increasing age.
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Background Osteoprotegerin (OPG) is a soluble decoy receptor that
acts as a receptor antagonist, blocking OPG ligand (OPGL) induced
osteoclastogenesis. In vitro, proinflammatory cytokines such as tumour
necrosis factor (TNF) upregulate endothelial OPG expression.
However, low levels of endothelial OPG expression are seen in synovial
biopsies from patients with active rheumatoid arthritis (RA) associated
with high levels of TNF. In order to elucidate the in vivo interaction
between TNF and the OPG/OPGL system in RA, we investigated the
effect of anti-TNF therapy on synovial expression of OPG and OPGL.
Methods OPG, OPGL and CD31 were evaluated by immunohisto-
chemistry in serial synovial biopsies obtained from 20 RA patients
before and after 8 weeks of treatment with Etanercept (Amgen and
Wyeth Pharmaceuticals, USA) or Infliximab (Schering-Plough, Stock-
holm, Sweden). Biopsies were evaluated by double-blind semiquantita-
tive analysis and image analysis. Statistical analysis was performed
using the Wilcoxon’s signed-rank test followed by Bonferroni correc-
tions for multiple comparisons.
Results OPG was expressed in all studied synovial biopsies, mainly in the
CD31-positive endothelial cells. OPGL expression was detected in syn-
ovial areas rich in T cells, with low expression in endothelial cells and
macrophages. Treatment with Infliximab significantly increased synovial
OPG expression whereas the increase in synovial OPG expression
observed after Etanercept treatment did not reach statistical significance.
Neither infliximab nor etanercept influenced OPGL expression following
8 weeks of treatment. The ratio between synovial OPGL and OPG expres-
sion decreased following treatment with infliximab (P< 0.05, after Bonfer-
roni comparisons) and etanercept (NS after Bonferroni correction).
Conclusion Our findings suggest a particular OPG–TNF interaction in
vivo as well as a potential difference in action between the two anti-
TNF agents tested.
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Background and Objective IL-20 is a novel cytokine that is involved in
skin inflammation, in part by serving as an autocrine factor for ker-
atinocytes. The aim of this study was to investigate the expression of
IL-20 in the inflamed synovium of patients with psoriatic arthritis (PsA)
and rheumatoid arthritis (RA) to provide more insight into the possible
role of this cytokine in inflammatory joint disease. To further assess the
regulation of IL-20 expression, in vitro experiments were conducted to
determine the effects of IL-1β and TNF-α on the expression of IL-20 by
RA fibroblast-like synoviocytes (FLS).
Methods Synovial biopsy specimens of patients with PsA (n = 11) and
RA (n = 10) were obtained from actively inflamed joints by needle
arthroscopy. Immunohistologic analysis was performed using a mono-
clonal antibody (mAb) specific for IL-20. In addition, we measured
IL-20 expression in RA FLS in the presence or absence of 250 pg/ml
IL-1β and 100 ng/ml TNF-α by immunocytochemistry.
Results IL-20 was expressed in the intimal lining layer, in the synovial
sublining and on endothelium in both PsA and RA patients. Digital
microscopic analysis of synovial tissue revealed clear IL-20 expression
with comparable overall scores in both patient groups (RA
149775 ± 56466, PsA 123862 ± 50630 [mean integrated optical
density ± SEM]; NS). The in vitro experiments revealed marked induc-
tion of IL-20 after stimulation with IL-1β and TNF-α in RA FLS.
Conclusion IL-20 expression is induced in FLS by proinflammatory
cytokines, including TNF-α and IL-1β. In addition, IL-20 is markedly
expressed in psoriatic skin lesions, but also in the synovium of patients with
PsA and RA, suggesting a role in various forms of inflammatory joint disease.
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Cross-talk between TRAIL and TGF-β β in regulation of
collagen production in scleroderma lung disease
VV Yurovsky
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Background Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a TNF family member, which has been closely associated with
Available online http://arthritis-research.com/supplements/6/S1S10
regulation of the immune response and pathogenesis of autoimmune
diseases. The expression of TRAIL was found in CD8 T cells that had
undergone oligoclonal expansion in the lungs of patients with systemic
sclerosis (scleroderma) and were able to stimulate collagen production
in lung fibroblasts in vitro. Among the family members, TRAIL displays
highest homology to Fas ligand, the receptor of which may mediate not
only cell apoptosis but also the proliferation of normal human fibroblasts.
Objective Considering structural and functional similarities between
TRAIL and Fas ligand, we examined the effects of soluble multimerized
TRAIL on normal human lung fibroblasts.
Methods and Results TRAIL at doses in excess of 100 ng/ml induced
apoptotic death of fibroblasts. However, at lower concentrations it was
found to stimulate collagen production. Collagen alpha2(I) mRNA
expression was assessed by real-time RT-PCR; and total soluble colla-
gen was measured in culture supernatants using the Sircol assay. Both
alpha2(I) collagen mRNA and total soluble collagen were increased
upon TRAIL stimulation, with peak response (more than fourfold
increase in mRNA) at 1 ng/ml TRAIL. DNA microarray analysis revealed
TRAIL-induced increase in the expression of a number of genes
involved in tissue remodeling, including those related to the transform-
ing growth factor (TGF)-β pathway. The microarray results were con-
firmed by Northern blot analysis of TGF-β1 mRNA expression and by
measurements of total active TGF-β1 in culture supernatants. In addi-
tion, antibody-mediated blocking of TGF-β was shown to abrogate
TRAIL-induced collagen synthesis.
Conclusion These data suggest that TRAIL can enhance extracellular
matrix production in fibroblasts by triggering TGF-β expression, which
acts in an autocrine manner. If this process continues uncontrolled, it
may contribute to the development of fibrosis, particularly in the lungs
of patients with scleroderma.
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Background and Objective The function of immune cells is dependent
upon a constant and adequate supply of energy (ATP), which is mainly
formed by oxidative phosphorylation (OXPHOS). In arthritis, microenvi-
ronmental conditions are characterized by low levels of oxygen and
glucose. Thus, effector cells of the innate immune system are recruited
to sites where they face an acute need to respond to these demanding
conditions. We investigated how immune cells maintain viability and
function under these circumstances, and which immune processes are
limited to what extent by energy deficiency.
Methods From peripheral mononuclear cells obtained from healthy
donors, we isolated CD4+ T-cells (MACS, >98% purity) and incubated
them (37°C, 5% CO2) in RPMI 1640 with 11.1 mmol/l glucose (permits
OXPHOS and glycolysis) and without glucose (permits OXPHOS only).
As a measure of oxidative ATP formation, cellular oxygen consumption
was determined amperometrically with a Clark electrode. Under the
conditions of unaffected ATP production and ATP production inhibited
stepwise using myxothiazole, PMA/ionomycin-stimulated cytokine pro-
duction (IL-2, IL-4, IFN-γ, TNF-α, 6 hours) and anti-CD3-/anti-CD28-
stimulated proliferation (over 96 hours) were quantified.
Results In the glucose-containing medium, both stimulated cytokine
production and proliferation were unaffected, even under complete
suppression of OXPHOS. Only when OXPHOS and glycolysis were
suppressed simultaneously and almost completely were cytokine pro-
duction and proliferation significantly decreased.
Conclusions We have quantified the energy requirement of specific
immune functions in human CD4+ T cells. Under maximally inhibited
OXPHOS, glycolysis fully compensates for the ATP supply for the energy
requirements of the immune functions investigated. These data demon-
strate a high adaptive potential of CD4+ T cells to maintain specific
immune functions even under massively impaired energetic conditions.
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Objective In this study we examined the effect of glucocorticosteroids
(GCs) in chronic arthritis on IL-1α, IL-1β, TNF and the newly discov-
ered proinflammatory cytokine HMGB1, which was previously thought
of only as a DNA-binding protein.
Methods Seventeen chronic inflammatory arthritis patients with
swelling and pain in at least one large joint were chosen. Synovial biop-
sies were sampled by arthroscopy before and 9–12 days after intra-
articular injection of 40 mg triamcinolone hexacetonide. Synovial
membrane T cells (CD3), macrophages (CD68, CD163), as well as the
proinflammatory cytokines IL-1α, IL-1β, TNF and HMGB1 were studied
by immunohistochemistry followed by semiquantitative analysis and/or
digital image analysis.
Results All investigated joints had clinical signs of active arthritis with
swelling and pain of the joint before treatment, which was reduced in
all joints after treatment. Numbers of T cells were reduced whereas
numbers of macrophages were not significantly changed. Expression of
HMGB1 was significantly reduced, whereas no significant effects were
seen on the expression of IL-1α, IL-1β or TNF. Before treatment
HMGB1 staining was mainly extracellular and cytoplasmic in the
mononuclear inflammatory follicles and lining layer, whereas endothelial
cells of scattered capillaries, arterioles and venules had a primarily
cytoplasmic staining. After treatment staining pattern was more promi-
nent in the nucleus and reduced extracellularly.
Conclusions Proinflammatory cytokines in chronic arthritis are affected
differently by intra-articular GCs. The marked reduction in HMGB1
expression and the lack of significant change in IL-1 and TNF thus indi-
cate that GCs may exert their in vivo effects in arthritis via partly differ-
ent pathways than in previous in vitro experiments.
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Human adipose tissue: an important novel source of
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The increased production of proinflammatory IL-1, TNF-α and IL-6 is
part of the pathogenesis of various immunoinflammatory diseases, often
accompanied by metabolic and cardiovascular complications. Cachexia
and obesity have been shown to accompany these diseases, and the
cytokines IL-1, TNF-α, IL-6 are said to be increased in white adipose
tissue (WAT). Few studies have been conducted to examine counter-
regulatory mechanisms of cytokine inhibitors. Sera of obese patients
showed a more than sevenfold increase in IL-1Ra, which matches levels
present in inflammatory autoimmune diseases and sepsis, and corre-
lates with body mass index and insulin resistance. Subcutaneous and
visceral human WAT of obese patients contained 0.4 and 0.7 ng of
IL-1Ra/mg protein, respectively. Thus, in an obese individual weighing
120 kg with 50% body fat, total WAT is estimated to contain 0.6 mg
IL-1Ra protein (i.e. 200 times the amount of IL-1Ra in total serum), thus
representing one of the main sources of IL-1Ra production. The
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increased IL-1Ra expression – not associated with an increase in IL-1β
– argues for an anti-inflammatory, compensating mechanism associated
with obesity. Our experiments with human WAT explants showed a
strong stimulatory effect of PMA and, more importantly, of IFN-β (as
much as 5- to 10-fold). Because the latter is a fibroblast-derived IFN, it
is tempting to speculate that stromal cells and adipocytes might be part
of a paracrine mechanism that regulates IL-1Ra secretion. In fact, newly
formed adipose tissue is often found close to inflammatory lesions (i.e.
synovial tissue). The functional consequences of the increased produc-
tion of IL-1Ra by adipose tissue may represent an important counter-
regulatory mechanism to inflammation at the local level. Furthermore,
IL-1RI and IL-1 IL-1RAcP were also expressed in human WAT. Thus,
substances that increase the production ratio of IL-1Ra/IL-1β by
adipose tissue might serve as a novel target for therapeutic strategies in
human immunoinflammatory diseases.
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Background In the murine macrophage-mediated SCW-induced
arthritis, IL-1 plays a dominant role in cartilage destruction, as was
shown in previous studies using cytokine gene knockout mice or anti-
bodies against IL-1. T cell IL-17 is a proinflammatory cytokine that has
many IL-1-like activities. IL-17 is expressed in the synovium of RA
patients and may play a role in rheumatoid arthritis (RA) pathology.
Objective In the present study we examined the potency of T cell IL-17
to bypass the relative IL-1 dependency of cartilage damage during
macrophage-driven SCW-induced arthritis.
Methods SCW-arthritis was induced in IL-1 deficient mice and their
C57Bl/6 controls by intra-articular injection of 25 µg SCW fragments.
Sixteen hours before the induction of arthritis, an adenoviral vector
expressing murine IL-17 or a control virus was injected into the knee
joint. Total knee joints were isolated for histological analysis of joint
inflammation by H&E staining and cartilage damage was measured as
proteoglycan (PG) depletion by Safranin O staining.
Results During SCW-induced arthritis, cartilage damage was clearly
suppressed in IL-1 deficient mice. Overexpression of T cell IL-17 in the
SCW arthritis model caused aggravation of the synovial inflammation
and induces more severe PG depletion. IL-1–/– mice showed the same
influx of inflammatory cells and comparable degree of cartilage damage
as control mice (Fig. 1), indicating that overexpression of IL-17 causes
loss of IL-1 dependency in this model.
Discussion These data show circumvention of the IL-1 dependency of
cartilage damage by T cell IL-17 in the macrophage-driven SCW arthri-
tis model. IL-1 and its receptor share the same signaling pathway
through TRAF-6 and NF-κB as IL-17. These data suggest that T cell
IL-17 can replace the catabolic function of IL-1 regarding cartilage
damage, directly or via interplay with other macrophage-driven factors.
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Background We recently found that overexpression of the Th1
cytokine IFN-γ during immune complex arthritis (ICA) resulted in deteri-
oration of matrix metalloproteinase (MMP)-mediated VDIPEN expres-
sion. On the contrary, overexpression of a Th2 cytokine might protect
against cartilage destruction.
Objective The aim of the study was to investigate whether local overex-
pression of the Th2 cytokine IL13 by gene transfer is able to diminish
MMP-mediated VDIPEN expression during ICA and, if so, what mecha-
nism is involved.
Methods Human IL-13 (hIL-13) was locally overexpressed in the knee
joint using an adenovirus (AdhIL13) and hIL-13 was detected in syn-
ovial washouts after 1, 2, 3, and 7 days. ICA was induced in C57Bl/6
by ia injection of lysozyme–antilysozyme complexes 1 day after
AdhIL13 injection. Histology and synovium specimens were taken at
days 1, 3 and 7 after ICA onset. Joint inflammation and MMP-mediated
VDIPEN expression were determined. mRNA levels of MMP-3,
MMP-12, and MMP-13 were detected in the synovium by Q-PCR.
Results AdhIL13 injected in naïve knee joints results in 1000 pg/ml
hIL-13 after 1 day, and increased to 3000 pg/ml detected at days 2, 3
and 7. Surprisingly, IL-13 did not diminish joint inflammation, because
the influx of inflammatory cells was similar in the Addel70 and AdhIL13
group. MMP-mediated VDIPEN expression was not found 1 day after
ICA onset because of the early time point. At day 3, IL-13 overexpres-
sion resulted in a twofold reduction in VDIPEN expression and a three-
fold reduction at day 7, compared with the control group. This
decrease might be the result of a declined production of MMPs.
However, the mRNA level of MMP-3 was comparable between the two
groups, whereas MMP-12 and MMP-13 mRNA levels were three times
higher in the IL-13 group.
Conclusion IL-13 overexpression during ICA does not alter the inflam-
matory response. VDIPEN expression was decreased, but this was not
reflected by declined MMP production, suggesting that IL-13 interferes
at the level of activation of pro-MMPs.
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Objective To study the role of TNF in sacroiliitis using a TNF-α trans-
genic (hTNFtg) mouse model.
Available online http://arthritis-research.com/supplements/6/S1
Figure 1
PG depletion 10 days after induction of SCW arthritis, in combination
with the ia injection of control virus or AdIL-17.
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Methods hTNFtg mice were divided into two groups receiving either
phosphate-buffered saline (PBS) or anti-TNF (infliximab). Wild-type
mice served as negative control. Treatment was initiated at week 4 and
continued over 6 weeks. Thereafter the sacroiliic joints were histologi-
cally assessed for joints inflammation, local bone erosion and cartilage
destruction.
Results. All hTNFtg mice showed a severe bilateral sacroiliitis. Treat-
ment of hTNFtg mice with anti-TNF, however, resulted in a significant
(P < 0.05), over 80% reduction in sacroiliacal inflammation. Further-
more, in hTNFtg mice severe erosions of the iliac as well as sacral sub-
chondral bones were detectable, whereas treatment with anti-TNF
virtually abrogated local bone erosions indicated by a reduction by over
99%. In addition, application of anti-TNF also significantly (P < 0.05)
reduced the numbers of osteoclasts at the front of erosions by 98%
compared with PBS-treated hTNFtg mice. The amount of sacroiliac
cartilage of hTNFtg mice was significantly (P < 0.05) reduced by 73%
compared with anti-TNF treated mice.
Conclusion These data clearly indicate that TNF overexpression
causes bilateral, erosive sacroiliitis and that anti-TNF therapy is a suit-
able tool with which to treat this condition.
Major histocompatibility complex
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Background HnRNP-A2 (RA33) is a multifunctional RNA-binding
protein involved in various aspects of post-transcriptional regulation of
gene expression. Autoantibodies to A2/RA33 are present in approxi-
mately 30% of rheumatoid arthritis (RA) patients whereas autoreactive
T cells have been found in almost 60% of the patients.
Objective The aim of the study was to analyze the T cell response to
A2/RA33 and its possible involvement in the pathogenesis of RA.
Methods The Tepitope programme as well as ELISAs were used to
define peptide sequences within A2/RA33 that may bind to the RA
associated MHC molecules HLA-DR*0401 and DR*0404. Candidate
peptides were analyzed in vivo by immunizing DR*0401 transgenic (tg)
mice and restimulating lymph node cells or purified CD4+ or CD8+
T cells with the peptides. The potential of A2/RA33 to induce disease
was studied by immunizing arthritis-prone DBA/1 mice, a strain bearing
the DR*0401 transgene on the DBA/1 background and TNF tg mice
(which spontaneously develop erosive arthritis).
Results Immunogenic sequences were found clustered in the RNA
binding domains of A2/RA33. In immunized HLA-DR4 tg mice the
reaction to A2/RA33 peptides seemed to be entirely produced by
CD4+ T cells showing a Th1 phenotype, with some of the peptides
inducing high production of IFN-γ. However, immunization of HLA-DR4
tg or DBA/1 mice with A2/RA33 protein induced only mild swellings in
some animals with no pathological findings in the histological analysis.
On the other hand, immunization of TNF tg mice enhanced arthritis sig-
nificantly. These mice overexpressed A2/RA33 in the joint, whereas
expression was very low in wild-type mice.
Conclusion A2/RA33 derived peptides can bind to RA associated
HLA class II molecules and induce a proinflammmatory Th1 response.
The increased arthritis observed in immunized TNF tg mice suggests
that the autoimmune response to A2/RA33 may indeed be involved in
the pathogenesis of RA by inducing or enhancing disease in a proin-
flammatory environment.
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Objective The role of HLA class II molecules in the pathogenesis of
rheumatoid arthritis (RA) is unclear. HLA class II molecules are involved
in the interaction between T and B lymphocytes required for long-lived
B-cell responses and generation of high-affinity IgG antibodies. The
relationship between HLA class II polymorphisms and RA-specific IgG
anti-cyclic citrullinated peptide (CCP) antibodies was investigated.
Methods High-resolution HLA-DR and DQ typing and anti-CCP2 anti-
body testing was performed in 279 RA patients from the Leiden Early
Arthritis cohort. The presence of anti-CCP antibodies was analyzed in
carriers of the different DR and DQ alleles. Disease progression was
measured over a period of 4 years by scoring radiographs of hands and
feet using the Sharp/Van der Heijde method.
Results Carriers of DQ-DR genotypes containing proposed RA sus-
ceptibility alleles were significantly more frequently anti-CCP antibody
positive. Carriership of one or two HLA-DRB1 shared epitope (SE)
alleles was significantly associated with production of anti-CCP anti-
bodies (OR 2.9, 95% CI 1.6–5.2 and OR 10.2, 95% CI 3.8–28.5,
respectively). In SE carrying, anti-CCP antibody positive patients an
increased rate of joint destruction was observed (mean Sharp score
7.6 points/year) compared with non-SE carrying, anti-CCP positive
(2.4 points;  P = 0.03), SE carrying, anti-CCP-negative patients
(1.6 points;  P < 0.001) and non-SE carrying, anti-CCP negative
patients (1.6 points; P < 0.001).
Conclusions Anti-CCP antibodies are associated with HLA class II RA
susceptibility alleles and presence of both factors is indicative of a
severe disease course. As the principal role of HLA class II molecules
is antigen presentation to T cells, these data point toward a pivotal role
of citrulline-directed T cells in the production of anti-CCP antibodies.
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Objective and Methods Antigenic peptides anchor by amino acid
residues to pockets within the antigen-binding groove of the HLA-
DRB1 molecule. In order to assess whether a pocket-wise analysis of
HLA-encoded susceptibility might provide a better fit to the immuno-
genetic data in rheumatoid arthritis (RA) than the shared epitope
hypothesis, HLA-DRB1 typing findings in 167 patients with recent
onset RA and in 166 controls were analyzed.
Results The shared epitope (residues 67–74) borders pockets 4 and
7. After stratification for pocket 4, polymorphisms in pocket 7 did not
influence RA risk. However, after stratification for pocket 7, both substi-
tutions in the α helix bordering pocket 4 and substitutions at position
13 in the floor of this pocket independently and significantly influenced
RA risk. Furthermore, substitutions at position 86 in pocket 1 also had
an effect on RA risk. Pairs of HLA-DRB1 alleles that only differ in the
glycine/valine dimorphism showed a consistent tendency toward
increased risk for the glycine variant in a pooled analysis (pooled OR
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1.66; p1 = 0.08). This observation is also strongly supported by data
from previous publications.
Conclusion Structural data indicate that HLA disease association may
be determined by the make-up of individual pockets within the antigen-
binding groove of the HLA molecule. In RA, susceptibility is influenced
by genetic polymorphisms in pocket 4 of the HLA-DRB1 molecule,
both in the floor of this pocket and in the α helix bordering this pocket.
In addition, genetic variation in pocket 1 modifies RA risk.
36
Influence of the physicochemical properties of the
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Objective HLA-DRB1 alleles encoding the shared epitope (SE) are
associated with rheumatoid arthritis (RA) but the underlying biological
mechanism is unknown. Several case–control studies have been pub-
lished on the protective effect of particular SE negative alleles, accord-
ing to the physicochemical properties of the fourth antigenic peptide
binding pocket (P4). The present study was undertaken to test those
hypotheses taking advantage of a familial based association analysis.
Methods One hundred French Caucasian families with one RA patient
and both parents were genotyped for HLA-DRB1. The analysis relied
on the allelic frequency calculation, the transmission disequilibrium test
(TDT) and the genotype relative risk analysis (GRR).
Results After the demonstration of the association of SE with RA in our
sample (P =4 . 8×1 0 –14), we replicated the strong protective effect of
HLA-DRB1*1501 alleles (P =4 . 7 7×1 0 –7). We also replicated a pro-
tective effect against RA of the alleles with an isoleucine at position 67
(P =1 . 9 3×1 0 –5) and the alleles with an aspartic acid at position 70
(P =3×1 0 –3). We failed to replicate any protective effect of the alleles
with a neutral or negative electric charge of the P4 pocket, nor a modu-
lation of SE effect by those alleles. We also failed to replicate the pro-
tective effect of Q and De alleles according to the functional
categorization of HLA-DRB1 alleles.
Conclusion Our findings are in keeping with a protective effect against
RA of SE negative alleles (HLA-DRB1*1501, alleles with an isoleucine
at position 67 and alleles with an aspartic acid at position 70).
T-cells
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Background CD4+ T cells lacking the costimulatory molecule CD28
have been described in both elderly individuals and in several chronic
inflammatory disorders, one being rheumatoid arthritis (RA).
Objective We characterized such CD28nullCD4+ T cells from RA
patients in order to identify surface markers correlating with function.
Methods Peripheral blood mononuclear cells were analyzed for
surface marker expression by flow cytometry and in vitro cultures were
set up for functional studies.
Results One-third of the RA patients had a persistent and expanded
CD28null population, which comprised up to half of the CD4+ T cells in
peripheral blood. Functionally, CD28nullCD4+ T cells were potent
effector memory cells with regard to their proliferation and cytokine
secretion profiles. This functional capacity correlated with a hitherto
unpublished surface phenotype, the cells being uniformly CCR7-nega-
tive and CD43high. In addition, we re-evaluated previously suggested
cell surface markers, and found CD57 and CD11b expressed on the
majority of these NKT-like CD4+ T cells. When combining phenotypic
and functional analyses of subpopulations of the CD28nullCD4+
T cells a new terminally differentiated T cell population was identified.
Conclusion We believe that in the balanced immune system of healthy
individuals, CD28nullCD4+ T cells are under homeostatic control,
whereas in an unbalanced immune system such as in autoimmune
disease CD28nullCD4+ T cells are allowed to expand and have the
capacity to enhance ongoing inflammatory reactions.
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Background All organisms contain naturally occurring haptens in the
form of enzyme cofactors bound covalently to apoproteins. One
example is flavine adenine dinucleotide (FAD). Autoantibodies recog-
nizing flavoproteins, with specificity for flavin or flavin-peptide were
described in patients with myocarditis or other muscular diseases.
Objective We wanted to test the hypothesis that FAD-peptide reactive
T cells exist in patients with acute myocarditis.
Methods Peripheral blood mononuclear cells (PBMNC) were tested in
vitro with a purified FAD-peptide (from a trypsin digested, affinity puri-
fied flavoprotein) or a synthetic peptide with the same amino acid
sequence. Proliferation was measured by 3H-TdR incorporation, and
the secretion of IFN-γ by ELISA.
Results PBMNC from four patients with acute myocarditis showed
positive responses to the FAD-peptide, in contrast to control individu-
als. The synthetic FAD-free peptide did not induce a response.
Conclusions The results are consistent with the hypothesis that during
the inflammation of the heart cardiomyocytes liberate normally cryptic
mitochondrial FAD-peptides, which induce a T cell response. Similar
mechanisms could be envisaged in inflammatory diseases of other
compartments (e.g. the joints in rheumatic diseases [1]).
Acknowledgement Supported by grants of the DFG.
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Background Shigella flexneri is one of the bacteria causing reactive
arthritis (ReA). However, no target antigen for the cellular and humoral
immune response against Shigella is yet known.
Methods Shigella were grown in culture followed by differential cen-
trifugation, after which a cytoplasmic and the 70S ribosomal fraction
were obtained. By means of density gradient centrifugation the 70S
ribosome was divided into its two subunits, the small ribosomal subunit
30S and the large ribosomal subunit 50S. The proteins derived from
both subunits were further separated by FPLC–ion exchange chro-
matography. Mononuclear cells from synovial fluid of 3 HLA-B27 posi-
tive patients with Shigella-induced ReA were stimulated with whole
Shigella, the cytoplasmic fraction, the ribosomal subunits and with
single protein fractions from the ribosomal subunits gained by FPLC.
Stimulatory protein fractions were subsequently cleaned by RP-HPLC
and identified by stamp-size 2D PAGE.
Results Seventeen protein fractions from the 30S subunit and
23 protein fractions from the 50S subunit were obtained. A lymphocyte
proliferation was seen after stimulation with whole Shigella, with the
cytoplasmic fraction and the two ribosomal subunits but not with control
antigens. More interestingly, five single ribosomal proteins out of 40
were equally stimulatory in all three patients, indicating that they repre-
sent immunodominant T cell antigens. Characterization by 2D PAGE
identified the ribosomal proteins L15, L18, L21, L22 and L23 from 50S
(‘L’ for large subunit) and S3 from the 30S (‘S’ for small subunit).
Conclusion This approach allows the identification of T-cell epitopes
derived from bacteria in ReA patients. In a first step we identified pro-
teins from the highly conserved ribosomal fraction of Shigella flexneri.
Their role in the pathogenesis must be further investigated.
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Background Naturally occurring CD4+CD25+ T cells have been
shown to suppress immune responses both in vivo and in vitro. Finding
a way to harness their regulatory abilities is of particular value in both
transplantation and autoimmunity, where unwanted immune reactions
need to be eliminated. Tantalizing evidence for their future potential is
demonstrated by their ability to cure T cell mediated colitis induced in
SCID mice [1]. However, many autoimmune diseases display a strong
humoral component, such as rheumatoid arthritis. It is unknown
whether CD4+CD25+ T cells are effective in these B cell-mediated
autoimmune diseases.
Objective We tested the ability of CD4+CD25+ T cells to modulate
collagen-induced arthritis (CIA), a disease dependent on the presence
of B cells [2].
Methods In order to determine the role of endogenous CD25+ T cells
in CIA, CD25+ cells were first depleted in mice before immunizations to
induce CIA. The therapeutic value of these cells was assessed by
adoptively transferring preactivated CD4+CD25+ T cells into mice
during the onset of disease.
Results Depletion of CD25+ cells before CIA induction lead to a has-
tened severe disease in comparison with nondepleted control mice. If
CD4+CD25+ T cells were transferred to mice therapeutically, the mice
had a significantly milder disease.
Conclusion CD4+CD25+ T cells can treat chronic arthritis and proba-
bly have the potential to treat a wide spectrum of autoimmune dis-
eases, including those that are mainly mediated by B cells.
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Background Lupus nephritis is one of the hallmarks of systemic lupus
erythematosus (SLE). Although there is increasing evidence that these
T lymphocytes might play a major role in the initiation and maintenance
of nephritis, there is hardly any functional data about these cells.
Objective The aim of the present study was to characterize kindey infil-
trating T cells with respect to their activation state, their memory/effector
phenotype, proliferation, and cytokine production. Furthermore, the ability
to provide T cell help for the generation of autoantibodies was tested.
Methods CD4+ T cells derived from inflamed kidney tissues of 7- to
9-month-old NZB/W F1 mice were analyzed for the expression of
CD69, CD25, CD28, CD62L, CD45RB, CD44, and CD71 by FACS.
Furthermore, intracellular cytokine staining was measured after
PMA/Ionomycin stimulation, and the ability of kidney T cells to respond
to the SmD1 83-119 peptide with increased generation of anti-dsDNA
antibodies was tested by ELISPOT.
Results and Conclusion The kidney infiltrating CD4+ T cells were highly
activated in terms of CD69 expression (28%). The expression of CD25
was lower compared with splenic T cells (8.6% versus 15.2%). The
CD4+ T cells were mainly of the effector/memory phenotype (55–60%),
but there was also a high frequency of naïve T cells (40–45%).There was
a low frequency of proliferating T cells (5%), as detected by CD71
expression. Most T cells were of the Th1 phenotype and produce proin-
flammatory cytokines such as IFN-γ (16.8%) and TNF-α (11.8%). Kidney
T cells give no help for the generation of anti-dsDNA antibodies.
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Background CD25+CD4+ regulatory T cells participate in the regula-
tion of immune responses. We recently demonstrated an enrichment of
CD25brightCD4+ T cells with a capacity to control T cell proliferation
in the joints of patients with rheumatoid arthritis (RA).
Objective  Here, we extend these studies to investigate a possible
accumulation of regulatory T cells in the joints of other inflammatory dis-
eases, and their potential to suppress cytokine production in patients
with rheumatic diseases, including RA.
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Methods Synovial fluid and peripheral blood samples were
obtained during relapse from 204 patients with spondy-
loarthropathies, juvenile chronic arthritis, and RA, and the frequency
of CD25brightCD4+ T cells was determined. For functional studies,
synovial cells from six patients were sorted by flow cytometry and
the suppressive capacity of these CD25brightCD4+ T cells was
determined in in vitro coculture.
Results Of 204 patients, 198 patients exhibited a higher frequency
of CD25brightCD4+ T cells in synovial fluid as compared with
peripheral blood. Additionally, in comparison with healthy individuals,
the patients had significantly fewer CD25brightCD4+ T cells in
peripheral blood. Functionally, the CD25brightCD4+ T cells sup-
pressed both type 1 and 2 cytokine production, and proliferation,
independent of diagnosis.
Conclusion Irrespective of diagnosis of the inflammatory joint disease,
an accumulation of CD25brightCD4+ T cells in the joint and reduced
numbers in peripheral blood suggest an active recruitment of regulatory
T cells to the affected joint. Their capacity to suppress both prolifera-
tion and cytokine secretion might contribute to dampen the local
inflammatory processes.
Dendritic cells
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Background Dendritic cells (DCs) are the professional antigen-pre-
senting cells that produce a large set of chemokines. Recent evidence
suggests that DCs, by their production of chemokines, are important in
the inflammatory cascade.
Objective The aim of the study was to evaluate the expression of
chemokines by DCs and synovial tissue from patients with RA in com-
parison with that from healthy individuals.
Methods Immature and mature DCs were obtained using standardized
protocols as described previously. The expression of the chemokines
DC-CK1, ELC, IL-8, MIP-1a, SDF-1a, SDF-1a, lymphotactin, SLC,
MIP-3a, TARC and MDC in iDCs, mDCS and synovial tissue was
determined by using real-time quantitative RT-PCR techniques
(PRISM).
Results iDCs of RA patients (n = 10) express low levels of ELC and
MIP-1a, and high levels of MDC and TARC, which were equal when
compared with DCs from healthy individuals (n = 8). However, the
expression of DC-CK1 (P < 0.001) and IL-8 (P = 0.02) by iDCs from
RA patients was significantly higher. After full maturation, expressions
of DC-CK1 (P < 0.001), ELC (P < 0.001), IL-8 (P = 0.02), MIP-1a
(P < 0.001) and TARC (P < 0.001) were significantly higher in DCs
from RA patients relative to healthy donors. In RA synovial tissue,
DC-CK1 (230-fold), ELC (400-fold) and IL-8 (36-fold) were expressed
at much higher levels when compared with healthy individuals. TARC
was also expressed at higher levels in RA synovial tissue but this failed
to achieve significance.
Conclusion In DCs both from patients with RA and in biopsies of
rheumatoid synovium, significantly higher levels of DC-CK1, ELC and
IL-8 mRNA are present relative to their normal counterparts. MIP-1a
and TARC were expressed at higher levels exclusively by DCs from RA.
These results suggest that DC-CK1, ELC, MIP-1a and TARC, along
with DCs, play a critical role in RA.
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Objective We studied the immune response against pcDNA3.1 in a
model of rheumatoid arthritis (RA), namely collagen-induced arthritis
(CIA), to understand the role of innate immunity in RA and the inocuity
of this empty plasmid used in gene therapy.
Methods CIA was induced in DBA/1 mice by type II collagen sc injec-
tions. At D10 and D24 after immunization, 1 µg pcDNA3.1neo (CpG
islets-containing plasmid) or pCor (control plasmid) were injected in
lower limbs. DBA/1 BMDC were stimulated in vitro with
pcDNA3.1neo, pCor, LPS+/– TNF for 24 and 48 hours. BMDC were
analyzed in flow cytometry, and IL-12, TNF-α, IFN-γ and IL-10 were
tested by ELISA in BMDC supernatants. BMDC endocytosis capacity
and MLR functional capacity were also studied. CIA was treated with a
stimulated dendritic cell population after immunization.
Results PcDNA3 decreases the incidence of arthritis in collagen
immunized DBA mice. Stimulation of BMDC with pcDNA3 increased
costimulation molecule expression, cytokine production (IL-12, TNF-α,
IFN-γ and IL-10), and allogeneic T cell proliferation, but at a lower level
than LPS stimulation. Moreover, pc DNA3 stimulated BMDC have
higher endocytosis capacity than LPS stimulated BMDC. Treatment of
collagen immunized mice with this steady-state activated-dendritic cell
population decreases the incidence of arthritis.
Conclusion We demonstrated that the stimulation of dendritic cells
with an empty plasmid, pcDNA3.1neo, could lead to a steady state of
activation that could support tolerance induction. This effect needs to
be further characterized and seems to be a ‘yes’ or ‘no’ answer, as inci-
dence is decreased but total clinical scores are not statistically modi-
fied. Histological studies will help to understand this mechanism.
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Background The RANK/RANKL pathway is critical in osteoclastogene-
sis and bone destruction, and is implicated in focal bone erosion in
rheumatoid arthritis (RA). Because deficient mice show major lymph
node (LN) abnormalities, here we looked at its involvement in the
immune response during chronic inflammation.
Methods We investigated, by immunohistochemistry, RANK and
RANKL expression by DC and T cell subsets in paired RA synovium–
LN and also in normal peripheral blood mononuclear cells (PBMC)
stimulated with PMA/PHA.
Results In RA synovium, RANKL+ cells were detected in the lining
layer and the lymphocytic infiltrates whereas RANK expression was
restricted to the perivascular infiltrates. In LN, RANK+ and RANKL+
cells were diffusely expressed in both T-cell zone and germinal centres.
Double staining with anti-RANK or anti-RANKL and anti-CD1a or anti-
DC-LAMP antibodies revealed that, in paired RA synovium-LN sec-
tions, some immature CD1a+ DC express RANK and RANKL whereas
some mature DC-LAMP+ DC expressed only RANK. Double staining
with the CD3, CD4 T-cell markers and the IFN-γ and IL-17 Th1 cell
markers showed that some of CD3+, CD4+, IFN-γ+ and IL-17+ cells
expressed RANKL, whereas none of them expressed RANK. The same
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pattern was observed on activated PBMC. The RANK+ cells, detected
in unstimulated PBMC, were identified as CD14+ monocytes.
Conclusion This study showed the involvement of RANK/RANKL in
DC–T cell interactions occurring during the inflammatory process. In
particular, RANK expression appears to be limited to the sites of
immune reaction both in synovium and LN.
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Background Rheumatoid arthritis (RA) is an autoimmune disease that
is characterized by chronic inflammation of the joints leading to
destruction of cartilage and bone. RA is characterized by synovial lining
hyperplasia and chronic infiltration by T and B cells,
monocyte/macrophages, dendritic cells (DC) and other cells. DC are
the only antigen-presenting cells that can prime naïve Th cells and initi-
ate immune responses. In peripheral blood two major DC subsets can
be found: BDCA1+CD11c+CD123low (myeloid), with the ability to
produce IL-12; and BDCA4+CD11c–CD123high (plasmacytoid),
which produce large amounts of type I interferons (IFN-α/β).
Objectives To gain insight into the in vivo characteristics of DC, we
investigated the distribution of BDCA1+ and BDCA4+ DC in RA
patients compared with healthy controls and non-RA patients.
Methods The frequencies of BDCA1+ and BDCA4+ DC in peripheral
blood and synovial fluid were analyzed by FACS analysis. Immunohisto-
chemistry was performed in synovial tissue from RA patients to get
more insight into the distribution of these two DC subsets in vivo.
Results We found that the frequencies of both BDCA1+ and BDCA4+
DC in peripheral blood of RA patients are decreased compared with
healthy controls and non-RA patients. Although the frequencies of both
DC subsets in synovial fluid from RA patients were increased com-
pared with peripheral blood, they did not differ significantly from non-
RA patients. In rheumatoid synovial tissue, both DC subsets were
localized close to CD3 and CD8 T cell infiltrates.
Conclusion BDCA1+ and BDCA4+ DC are preferentially localized in
the synovium of RA patients, where they could stimulate memory
T cells and sustain the inflammatory process. Conceivably, immuno-
modulation by targeting synovial DC might provide a novel anti-
rheumatic strategy.
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Background Dendritic cells (DC) from both myeloid and lymphoid
haematopoietic lineages comprise a complex network of professional
antigen-presenting cells, directly linking innate and adaptive immunity.
Although implicated in the pathogenesis of inflammatory arthritides,
their subset analysis has been hampered by a lack of specific DC
markers and reliable quantitation.
Objectives The study was conducted to quantify circulating plasmacy-
toid DC (pDC) and myeloid DC (mDC) populations in different chronic
inflammatory arthritides utilizing a novel assay involving the DC-specific
markers BDCA-1 and BDCA-2.
Methods Peripheral blood (PB) was obtained from RA (n = 12), PsA
(n = 13), AS (n = 11) and healthy donors (n = 12). Synovial fluids (SF)
were also examined from a subset of PB samples (4 RA, 2 PsA, 1 AS).
A white blood count (WBC) was performed on all samples, followed by
DC enumeration using the blood DC enumeration kit (Miltenyi Biotec).
Results Circulating PB mDC populations were significantly decreased
in RA patients (P = 0.004), but not in PsA or AS patients, compared
with healthy donors (normal = 175 × 102,  R A=9 5 . 5×1 0 2, PsA =
1 4 1×1 0 2,  A S=1 5 2×1 0 2). Circulating PB pDC populations were
significantly decreased in RA (P = 0.01) and PsA (P = 0.01) but not
AS patients (normal = 137 × 102,  R A=5 4 . 6×1 0 2, PsA = 69.5 × 102,
A S=1 0 4×1 0 2). The mDC : pDC ratio in PB of all patient groups was
similar to that in healthy donors, whereas mDC exceeded pDC in SF in
all patient cohorts analyzed (RA 6.6:1, PsA 7.35:1 and AS 100:1).
Conclusions We report the ex vivo tracking of circulating pDC and
mDC populations, revealing significantly reduced numbers of pDC in
RA and PsA and mDC in RA patients. mDC subsets appear to be the
predominant population in SF in all patient cohorts studied. Under-
standing the biology of DC subsets in chronic inflammatory arthritis will
elucidate their presumed critical role at the interface of innate and
acquired (autoreactive) immune responses.
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Introduction Dendritic cells (DCs) determine the balance between tol-
erance and immunity in which Fc γ receptors (FcγR) are thought to play
a decisive role. Previously, we found that DCs from RA patients
expressed a different FcγR profile.
Objective The aim of the study was to determine the potential differ-
ence in chemokine expression and production between DC from RA
patients and healthy controls upon FcγR mediated triggering.
Methods Immature and mature DC were obtained using standardized
protocols as described recently. The expressions of the chemokines
DC-CK1, ELC, IL-8, MIP-1a, TARC and MDC were determined by
using real-time quantitative RT-PCR techniques (PRISM). The produc-
tion of DC-CK1 was confirmed by using ELISA techniques. Triggering
of FcγR was achieved by the addition of heat aggregated IgG
immunoglobulins (HAGGS) to the culture for 48 hours.
Results Stimulation of FcγR resulted in a significantly decreased
expression of DC-CK1 (35%), ELC (50%), IL-8 (640%) and TARC
(39%) by DC from RA patients (n = 6). Although not significant, the
same trend was observed for MIP-1a (160%). In contrast, a significant
increase was seen for DC-CK1 (300%), ELC (120%), IL-8 (640%),
MIP-1a (160%) and TARC (39%) upon triggering of FcγR on DC from
healthy individuals (n = 5). MDC was the only chemokine that showed
a decrease upon FcγR dependent stimulation of DC in both groups. By
using ELISA techniques, we confirmed these data for DC-CK1 on the
protein level. Triggering of FcγR led to a decreased (63%) production
of DC-CK1 by DC from RA patients, whereas an increase (137%) was
observed by those from controls.
Conclusion Our study lends strong support for a skewed FcγR
balance toward the inhibitory subtype in RA, and shows the critical role
for FcγR in the inhibition of chemokine production by DCs. Further-
more, our data show that FcγR triggering influences Toll-like receptor
(LPS) mediated cell responses.
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Background Systemic lupus erythematodes (SLE) represents an
autoimmune disease for which alterations in T cells, B cells as well as
various antigen-presenting cell (APC) populations have been described.
Objective In order to better define APC-associated deficiencies we
analyzed morphologic, phenotypic and functional characteristics of
dendritic cells (DC) from SLE in patients as compared with healthy
controls.
Methods Monocyte derived DC (MoDC) were generated by culturing
monocytes with GM-CSF+IL-4 for 8 days and with LPS for additional
2 days. MoDC were analyzed at different stages of maturation for mor-
phologic, phenotypic and functional characteristics.
Results and Conclusion Analysis of MoDC at different stages of mat-
uration revealed substantial phenotypic and functional defects of
MoDC from SLE as compared with healthy controls. In particular, we
observed a significantly reduced upregulation of MHC class II mole-
cules on MoDC upon activation, which correlated with disease activity
scores and functional deficiencies in mixed lymphocyte reaction experi-
ments. Our data imply a crucial role of APC in the immunologic imbal-
ance in SLE for foreign- and self-antigen reactivity.
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Background and Objective Dendritic Cells (DCs) play an important
role in initiation and regulation of immune responses in arthritis,
because these cells are crucial for the initiation of T cell immunity. Full
mobilization of effector T cells depends on proper maturation of DCs.
Current evidence indicates that the type of T cell response indeed cru-
cially depends on the activation status of DC. For example, antigen
recognition on resting DCs can result in immuneregulation. In this study
we explored the immunological effects of differentially matured DCs on
the development of collagen-induced arthritis (CIA).
Methods Bone marrow derived DCs were cultured in the presence of
GM-CSF with or without IL-4. Immature, TNF-α or LPS activated,
antigen-pulsed DCs were used. At several time points before immu-
nization with bovine CII protein, mice were injected with DCs exposed
to these different maturation stimuli. Mice were boosted on day 21
post-CII-immunization and disease course was monitored.
Results Although vaccination with immature or LPS activated DCs had
no significant influence on disease course, administration of antigen-
loaded, TNF-α modulated DCs resulted in a delayed onset of arthritis
and a decreased clinical score. The effect was antigen-specific, as also
evidenced when antibody titres were measured. A specific increment in
the collagen-specific ‘Th1-associated’ IgG2a response was observed.
Remarkably, IgG1 was unaffected by this vaccination.
Conclusions CIA can be prevented through vaccination with TNF-α
matured DCs in an antigen-specific manner. These findings provide a
rational to employ DCs in treatment or prevention of arthritis.
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Objective Dendritic cells (DC) are thought to play an important role in
the pathogenesis of rheumatoid arthritis (RA). In RA, fully matured APC
are present in the inflamed synovial tissue clustered around activated
T cells. Because DC maturation and cytokine production are NF-κB
dependent, we hypothesized that blocking NF-κB activity in DC by
selectively targeting IKKβ with a specific NEMO binding domain (NBD)
peptide could inhibit the maturation of DC and thereby modulate the
immune response.
Methods Immature DC were obtained by culturing freshly isolated
monocytes in the presence of GM-CSF and IL-4. On day 6 immature
DC were incubated with the NBD peptide (WT versus MUT) in the
presence of maturation factors. DC were analyzed for NF-κB activity,
surface marker expression, cytokine production and interaction with
naive T cells. Furthermore, we investigated the effect of ia injection of
the NBD peptide in adjuvant arthritis in rats.
Results NF-κB blockade by the NBD peptide resulted in strongly
reduced maturation of DC. In addition, IL-6, IL-12 and TNF-α production
was dose dependently blocked. Interestingly, NBD peptide treatment
resulted in increased CCR7 expression. Coculture with naïve T cells
resulted in reduced proliferation and differentiation. In vivo, injection of
the NBD peptide resulted in reduced paw swelling in arthritic rats.
Conclusions Inhibiting NF-κB with the NBD peptide in DC results in an
immature phenotype with increased CCR7 expression. The enhanced
CCR7 expression may promote migration to draining lymph nodes and
presentation of antigen in the absence of costimulation. These data
strongly suggest that targeting NF-κB in DC could be beneficial in the
treatment of arthritis, which is supported by preliminary data in rat adju-
vant arthritis.
Joint destruction/tissue engineering
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Background and Objective CD44 mediates cell-matrix interaction and
is thought to play a role in cell adhesion, fusion and migration. Blocking
of CD44 is considered as potential target in the therapy of rheumatoid
arthritis.
Methods To elucidate the role of CD44 in arthritis, human TNF trans-
genic (hTNFtg) mice were crossed with CD44 knockout mice.
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Results Clinical evaluation revealed a significantly increased severity of
arthritis in CD44–/– hTNFtg mice than in hTNFtg mice. Wild-type mice
and CD44–/– mice were normal. Histologically, bone destruction was
dramatically increased in the arthritic paws of CD44–/– hTNFtg mice.
Changes were based on a significant increase of size and number of
osteoclasts in the synovial inflammatory tissue. Ex vivo analysis of osteo-
clastogenesis revealed that osteoclasts differentiated more rapidly and
were increased in size and number in CD44–/– hTNFtg mice compared
with hTNFtg controls. In addition, bone resorption assay showed
increased 'pit' formation by osteoclasts of CD44–/– hTNFtg mice.
Conclusion CD44 deficiency does not block but rather increases the
severity of TNF-mediated arthritis. This was due to increased bone
damage caused by deregulation of osteoclastogenesis. We conclude
that CD44 is of benefit for TNF-mediated arthritis because of its regula-
tory role on osteoclasts.
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Objectives In this study we attempted to map the molecular events
that underlie the clinical effects of glucocorticoid (GC) treatment in
patients.
Methods DNA arrays and immunohistochemical staining was used for
comparison of patient material isolated before and after intra-articular
glucocorticoid (GC) treatment. Gene expression data analysis was per-
formed in the GeneSpring™ software.
Results Hierarchical clustering of gene expression data could distin-
guish samples taken before from those taken after treatment to a sur-
prisingly high degree, in spite of anticipated individual and experimental
variations. Patterns were further analyzed by identification of genes
with both statistically significant differential expression (P < 0.05) using
the cross gene error model implemented in GeneSpring™, and greater
than twofold differential expression. Twelve genes satisfying both of
these criteria were found, including matrix metalloproteinase (MMP)-1
and MMP-3, for which mRNA expression was downregulated, and
tissue inhibitor of MMP (TIMP)-1 and TIMP-4, for which mRNA expres-
sion was upregulated by GC treatment. Immunohistochemical staining
for several MMP and TIMP molecules confirmed data for MMP-1 and
MMP-3 on a protein level, whereas the result for TIMP-1 and other
TIMPs revealed reduced protein expression of these molecules.
Conclusions Our data demonstrate that DNA arrays may be used for
evaluating the molecular effects of novel as well as established thera-
pies, but also that data should be interpreted with caution concerning
their ability to predict therapeutic effects at the protein level.
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Objective Interferon (IFN)-β is thought to inhibit the expression of
proinflammatory cytokines and to enhance the production of anti-
inflammatory proteins such as IL-1Ra. More recently it was shown that
IFN-β is important in maintaining homeostasis of bone resorption.
Because systemic treatment does not appear to be effective in RA
patients possibly because of the short half-life of IFN protein, we
studied the potential of intra-articular gene therapy using an adenoviral
vector to determine whether local constitutive expression of IFN-β in
the joint might have a beneficial effect.
Methods Three different dosages (109, 1010 and 1011 viral particles)
of an adenoviral vector containing the gene for rat IFN-β or LacZ
(Ad.IFN-beta and Ad.LacZ) were injected into the right ankle joints of
rats with adjuvant arthritis (AA) on day 12 after adjuvant immunization.
Joints were harvested 2 weeks later. The effect of IFN-β on paw
swelling measured by plethysmometry, bone degradation and histo-
logic joint damage was assessed.
Results In the rats treated with the highest dose of Ad.IFN-beta
reduced paw swelling was observed (P = 0.022 Ad.IFN-beta versus
Ad.LacZ). In addition, a clear reduction in paw swelling was seen in the
left uninjected paw. Moreover, the IFN-β-treated animals had signifi-
cantly less cartilage and bone destruction (P = 0.05) in both the right
and left paws as compared with control animals.
Conclusion We demonstrate that adenoviral in vivo gene transfer of
IFN-β cDNA into the synovium reduces the severity of inflammation of
AA in rats. In addition, an even more potent effect was found on articu-
lar cartilage and bone destruction. Furthermore, injection of Ad.IFN-
beta into a single paw can suppress inflammation and joint degradation
in the contralateral joints. Thus, treatment of a single joint by local deliv-
ery of the IFN-β gene could protect multiple joints.
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Chondrocytes express RANKL and its receptor RANK, implicating the
involvement of this pathway in cartilage damage. However, a direct role
of RANKL in cartilage destruction has not yet been identified. Here, we
used local and systemic osteoprotegerin (OPG) treatment to inactivate
RANKL in different arthritis models. We demonstrated that inactivation
of RANKL did not suppress cartilage breakdown in a local T-cell IL-17-
induced joint pathology, but completely prevented cartilage erosion in
collagen-induced arthritis, which is mediated by T cells and immune
complexes. Synovial inactivation of RANKL by local OPG gene therapy
in collagen-induced arthritis resulted in a chronic type 2 inflammation
characterized by abundant expression of IL-4 and protection of carti-
lage erosion. Microarray analysis revealed abundant expression of YM1
and arginase, which are specific markers of the macrophage M2 phe-
notype (alternative activated macrophage). Furthermore, protease spe-
cific inhibitors and Fc receptor type II are upregulated by OPG.
Changes in expression of catabolic mediators and inhibitors in the syn-
ovial infiltrate, including the key catabolic cytokine in cartilage destruc-
tion IL-1, contribute to the cartilage protective effect of OPG. These
data provide evidence that the cartilage protective effect of OPG in
collagen arthritis is mediated by induction of a nondestructive type 2
synovitis.
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expression of type II collagen and aggrecan in human
chondrocytes in 3D alginate cultures
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Background The healing capacity of articular cartilage is very limited in
the adult. Therefore, tissue engineering techniques were developed to
treat cartilage lesions.
Objective Because high expression of type II collagen is of importance
for the properties of cartilage after transplantation, we investigated
whether the growth factor BMP-2 may modulate the chondrogenic
phenotype in monolayer cell cultures (2D) and in three-dimensional
culture (3D) systems.
Methods Chondrocytes from articular knee cartilage of five individuals
were isolated and expanded under GMP conditions suitable for clinical
purposes. Cells were seeded either in 2D cultures or embedded in
alginate beads (3D) in the presence or absence of human recombinant
BMP-2 (hr-BMP-2). Then, cells were harvested and analysis of the
chondrogenic phenotype was performed using quantitative RT-PCR,
immunocytochemistry and ELISA methods.
Results Expansion of chondrocytes in primary culture (P0) or in first
subculture (P1) did not yield populations enriched for dedifferentiated
or hypertrophic cells, because type X collagen encoding mRNA was
detectable only at very low copy numbers. Seeding P1 chondrocytes in
3D culture significantly reduced type I collagen, BMP-4 and IL-18, and
induced type II collagen and BMP-2 encoding mRNA. Suppression of
IL-1β and induction of IL-10 were noted but were not statistically signif-
icant. At P2, these changes were still evident. Addition of BMP-2 to 2D
chondrocytes had no effect on type II collagen or IL-1β mRNA
amounts. In contrast, in 3D chondrocytes BMP-2 induced type II colla-
gen and reduced IL-1 mRNA amounts. This was also seen by ELISA
and immunocytochemistry.
Conclusions We conclude that chondrocytes during expansion for
ACT may benefit from BMP-2 activation only when seeded in an appro-
priate 3D culture system.
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Background We tested the hypothesis that a tissue engineering
approach using chemoattractant molecules will allow in situ recruit-
ment of human bone marrow mesenchymal stem cells (MSC) to sites
of degenerated articular cartilage.
Objective The aim of our ongoing study is to characterize molecules
that are involved in chondrogenesis and chemotaxis of MSC.
Methods Human bone marrow aspirates were used to isolate MSC.
The culture homogeneity was verified by FACS analysis (CD14–,
CD34–, CD45–, CD105+, CD166+). For differentiation, MSC were cen-
trifuged to form high-density cultures and different TGFs were added.
Chondrogenesis was documented by Alcian blue, type II collagen stain-
ing and by real-time PCR of marker genes. Chemotaxis was analyzed by
chemokine receptor analyses and transwell chamber assays.
Results The histological staining showed BMP-2 promotes differentia-
tion along the chondrogenic lineage. Matrix formation was comparable
to MSC stimulated with TGF-β3. The results suggest a synergistic stim-
ulation on chondrogenic differentiation with BMP-2 and TGF-β3. Differ-
entiation was further demonstrated by the induction of type II collagen,
aggrecan, SOX-9 and link protein on the gene expression level. Fur-
thermore, for the first time, expression of chemokine receptors of all
four chemokine subfamilies was proven by RT-PCR and subsequent
sequence analysis, as well as at the protein level using specific anti-
bodies. The chemotactic activity in 24-transwell chemotaxis chambers
was demonstrated for, for example, SDF1a.
Conclusion These findings demonstrate that chondrogenic development
of MSC is inducible by different TGF-β3 superfamily growth factors
including BMP-2. Additionally, MSC express chemokine receptors rele-
vant for chemotaxis or in situ recruitment for cartilage regeneration.
58
Requirement of local synovial IL-17 receptor
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IL-17 is a proinflammatory cytokine that is suspected to be involved in
development of rheumatoid arthritis (RA). However, the role of
IL-17–IL-17 receptor signaling in the effector phase of arthritis, includ-
ing requirement of this signaling pathway in synoviocytes, is still not
fully elucidated. Here we demonstrate, using IL-17 receptor deficient
(IL-17R–/–) mice, a requirement for IL-17R signaling in immune reactiv-
ity and progression of synovitis and bone erosion in a T cell mediated
mBSA arthritis model and chronic streptococcal cell wall arthritis. Of
great interest, chimeric mice of host wild-type (wt) and donor IL-17R–/–
bone marrow (BM) cells developed chronic synovitis similar to that in
wt/wt chimeras. In contrast, chimeric mice of host IL-17R–/– and donor
wt BM cells were protected from progressive synovitis similar to
IL-17R–/–/ IL-17R–/– chimeras, suggesting a crucial role of resident syn-
ovial cells. Weakened mobilization of neutrophils into the joint and
downregulation of synovial mRNA expression for leukocyte specific
chemokines and selectins, and MMP-1 was found in IL-17R–/– mice.
These data suggest that, in addition to the role played by IL-17–IL-17R
signaling in development of immunity, synovial IL-17–IL-17R signaling
plays a critical role in the effector phase of arthritis. Activation of IL-17R
on fibroblast-like synoviocytes appears pivotal.
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TRAIL-induced rheumatoid arthritis fibroblast-like
synoviocyte proliferation is inhibited by OPG
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TNF-α related apoptosis inducing ligand (TRAIL) is a proapoptotic
factor that can also induce cell proliferation. The role of TRAIL in
rheumatoid arthritis (RA) is still unclear. We investigated the effect of
TRAIL on RA fibroblast-like synoviocyte (FLS) proliferation. TRAIL
induces RA FLS proliferation in a dose-dependent manner, with a
maximum proliferation at 0.5 nmol/l (P < 0.05; n = 5). This proliferation
could be prevented by the natural TRAIL inhibitor osteoprotegerin
(OPG) and a TRAIL antibody. By flow cytometry, we analyzed TRAIL
receptors (DR4, DR5 and DcR2). RA FLS constitutively expressed
DR5 (n = 5) and three out five RA FLS expressed DR4. Interestingly,
RA FLS proliferate more after TRAIL stimulation when expressing both
Available online http://arthritis-research.com/supplements/6/S1S20
DR4 and DR5, suggesting a cumulative effect of the two receptors. DR5
receptor mediates the signal-inducing cell proliferation because stimula-
tion with an agonistic anti-DR5 antibody induces RA synoviocyte prolifer-
ation (n = 4; P < 0.05). Next, we investigated which cells in the synovium
could produce TRAIL and OPG. In RA FLS, TRAIL was detected at the
mRNA level after IL-1β and TNF-α stimulation but not at the protein level.
OPG was constitutively produced (2 ng/ml) and upregulated by IL-1β
(14-fold) and TNF-α (5-fold) but not IL-18. On RA synovial T cells, TRAIL
was constitutively expressed. Our results show that TRAIL induces RA
FLS proliferation. TRAIL produced on synovial T cells may interact with
RA FLS expressing DR4 and DR5 to induce FLS proliferation. OPG
inhibits TRAIL induced RA FLS proliferation. This novel propriety of OPG
may be another explanation for its bone protective role in RA.
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Expression of TRAIL-R2 (DR5) on fibroblasts from
synovial fluid of rheumatoid arthritis
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Fibroblasts can be isolated from rheumatoid arthritis (RA) synovial fluid
(Sfld), and these cells may be derived from the synovium. Although
normal tissues do not express DR5 protein, most cancerous tissues
express high levels of DR5. Synovial fibroblasts from RA synovium share
expression of DR5 protein with transformed cells. Our objective was to
characterize fibroblasts from RA Sfld using an anti-DR5 monoclonal
antibody. Sfld mononuclear cells were cultured from 50 patients with
RA, 20 patients with seronegative arthritis, 20 patients with osteoarthri-
tis (OA), and 15 patients with unclassified monoarthritis or oligoarthritis.
Progressive growth of spindle-shaped cells was observed in some cul-
tures. By the third passage 100% of cells were fibroblasts (Thy-1+,
CD45–, CD68–). Fibroblasts were stained with a PE-conjugated anti-
DR5 antibody and examined by flow cytometry. Fibroblasts grew from
35 of 50 RA Sfld samples. Twenty-six of these 35 were DR5+ (>95%
positive cells; MFI relative to isotype control, 13.97 ± 2.5). Fibroblasts
also grew from Sfld in six out of 20 seronegative arthritis, four out of
20 OA, and five out of 15 unclassified monoarthritis or oligoarthritis
patients. All these were DR5– (MFI relative to isotype control,
1.2 ± 0.23). Ten out of 10 fibroblast lines from joint replacement surgery
or synovectomy specimens of RA were DR5+. All fibroblast lines from
the synovium of 10 OA patients were DR5–, as were fibroblasts from the
skin of five healthy subjects. DR5+ Sfib cultures underwent apoptosis
when treated in vitro with an anti-DR5 antibody, as determined by pro-
pidium iodide and annexin V staining. These results suggest that fibrob-
last-like cells from Sfld of RA are of at least two different lineages. Those
expressing DR5 protein share this characteristic with transformed cells
and with synovial fibroblasts from RA synovial membrane, and more
likely derive from the synovium. The origin of DR5– Sfld fibroblasts
remains to be determined. Because all RA patients with DR5– Sfld
fibroblasts had active disease, we do not believe that DR5– cells are
derived from ‘burnt out’ synovial membrane.
61
The active metabolite of leflunomide, A77-1726,
increases proliferation of human synovial fibroblasts
in presence of IL-1β β
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Background Leflunomide is an immunomodulatory agent used for the
treatment of rheumatoid arthritis (RA) and is known to inhibit the prolif-
eration of several cell types, including T lymphocytes.
Objectives Because pannus formation due to excessive synoviocyte
proliferation is generally associated with the development of RA, we
sought to determine the effects of A77-1726, the active metabolite of
leflunomide, on synovial fibroblast proliferation.
Methods Cell viability was investigated by measuring at 490 nm the
formation of formazan from MTS tetrazolium, and cell proliferation by
determination of thymidine incorporation and cell counts.
Results Whereas A77-1726 alone had no significant effects on prolif-
eration, it dramatically increased the mitogenic effects of IL-1β. Then
we investigated the possible mechanisms of this effect of A77-1726
(i.e. inhibition of DHODH, of tyrosine kinases and COX). The effect
was not mediated through inhibition of DHODH because it was not
reversed by addition of exogenous uridine. It was not due to inhibition
of tyrosine kinases either, because the broad-range inhibitor genistein
and the src tyrosine kinase inhibitor PP1 blocked rather than increased
IL-1β effects. Finally, although in the absence of IL-1β PGE2 dose-
dependently decreased proliferation, it had no effect in the presence of
IL-1β, and treatment with indomethacin did not consistently reproduce
the effects of A77-1726.
Conclusions The mitogenic effects of A77-1726 in presence of IL-1β
may thus be independent on DHODH and tyrosine kinase inhibition,
whereas the role of COX is more uncertain; identification of involved
mechanisms may prove useful for the development of related com-
pounds or new therapeutic strategies.
Acknowledgement This work was supported by the Swiss National
Science Foundation (grant 3100-064123.00/1 to PAG) and by
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Background Focal and systemic bone loss in rheumatoid arthritis (RA)
involves several cytokines such as RANKL, which is secreted by both
osteoblasts and activated lymphocytes, and TNF-α. Anti-TNF-α anti-
bodies decrease articular inflammation and bone erosions, but the
effect on bone remains to be elucidated. Osteoprotegerin (OPG)
inhibits bone resorption.
Objective We conducted the study to evaluate the respective and
combined effect of OPG and anti-TNF-α antibodies on inflammation
and on bone remodelling.
Methods DBA/1 mice were immunized then treated at the onset of
arthritis with OPG-Fc or anti-TNF-α antibodies or with both OPG-Fc +
anti-TNF-α antibodies or saline; one group of mice remained untreated
(naïve). Deoxypyridinoline changes (∆D-Pyr) in urine, bone mineral
density gain (∆BMD) at the total body level, and histomorphometric
parameters at the femur metaphysis were measured.
Results Anti-TNF-α antibodies but not OPG decreased clinical and
histological scores (P < 0.02 versus saline). ∆BMD was lower in saline-
treated CIA mice than in naïve mice (P < 0.01), suggesting the effect of
inflammation on bone loss. OPG and anti-TNF-α antibodies increased
∆BMD compared with saline (P < 0.001 and P < 0.05, respectively).
∆D-Pyr decreased by 65% with OPG and by 7% with saline
(P < 0.001), but by 13% when mice were treated with TNF-α antibod-
ies (NS). Compared with saline, OPG induced increased trabecular
(Tb) bone volume (P < 0.02), decreased Tb spacing (P < 0.02) and
decreased BFR/BS (P < 0.01). In contrast, the anti-TNF-α antibody
treated group showed no significant changes in Tb bone volume and
Tb spacing compared with saline, but Tb thickness was greater
(P < 0.02), close to that in naïve mice, suggesting a protective effect
on bone formation. There was no additive effect of OPG and anti-
TNF-α antibodies on any parameter.
Conclusion Administration of OPG and anti-TNF-α antibodies pre-
vented bone loss in CIA mice through distinct mechanisms involving
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inhibition of bone resorption and formation. Combinations of both treat-
ments must be further investigated.
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Local bone erosion and systemic bone loss are hallmarks of rheuma-
toid arthritis and cause progressive disability. Tumour necrosis factor
(TNF) is a key mediator of arthritis and acts catabolically on bone by
stimulating bone resorption and inhibiting bone formation. We hypothe-
sized that the concerted action of anti-TNF, which reduces inflamma-
tion, and of PTH, which stimulates bone formation, or of OPG, which
blocks bone resorption, could lead to repair of local bone erosions and
reversal of systemic bone loss. To test this, human TNF-transgenic
(hTNFtg) mice with established erosive arthritis and systemic bone loss
were treated with PTH, OPG and anti-TNF, alone or in combination.
Local bone erosions almost fully regressed, upon combined treatment
with anti-TNF and PTH and/or OPG, suggesting repair of inflammatory
skeletal lesions. In contrast, OPG and anti-TNF alone led to arrest of
bone erosions but did not achieve repair. Treatment with PTH alone
had no influence on the progression of bone erosions. Local bone ero-
sions showed all signs of new bone formation such as the presence of
osteoblasts, osteoid formation and mineralization. Furthermore, sys-
temic bone loss was completely reversed upon combined treatment
and this effect was mediated by osteoblast stimulation and osteoclast
blockade. In summary, we conclude that local joint destruction and sys-
temic inflammatory bone loss due to TNF can regress, and that repair
requires a combined approach by reducing inflammation, blocking
bone resorption or stimulating bone formation.
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Background Oxidative stress is thought to underlie the altered patho-
genic behavior of T cells in rheumatoid arthritis (RA). We recently
demonstrated that intracellular signaling by Ras family GTPases leads to
ROS production in RA synovial fluid (SF) T cells. However, other cellular
sources of ROS may cause oxidative stress in RA synovial tissue (ST).
Objectives The study was conducted to determine whether T cells or
other cells spontaneously produce ROS in RA ST, to determine the
specificity of T cell ROS production in long-standing RA versus early
RA and osteoarthritis (OA) T cells, and to identify signaling pathways
producing ROS in RA ST and SF T cells.
Methods ROS production was assessed using ROS-dependent polymer-
ization of diaminobenzidine (DAB) on cryostat sections of ST from patients
with long-standing RA, early RA, and OA (n= 10 patients in each group),
purified RA patient peripheral blood (PB) and SF mononuclear cells, and
purified T cells (n= 4), and oxidation of the dye DCF by FACS analysis of
purified RA PB and SF T cells (n= 10), in the absence or presence of
pharmacological inhibitors. Cryostat sections were double labelled with
DAB and cell-specific antibodies to quantify ROS-producing cells.
Results ROS production was observed in both longstanding and early
RA, but not OA ST. ROS production was observed only in T cells
(68%) and neutrophils (15%). In RA ST, ROS producing T cells were
observed in the synovial sublining and perivascular tissue. Catalase
and BAPTA-AM, but not other ROS inhibitors, blocked ROS produc-
tion in ST and SF T cells. Intracellular ROS production is detected in
ST of patients with RA but not OA. T cells are the major source of intra-
cellular ROS production in RA ST. Conserved signaling pathways reg-
ulate ROS production in ST, SF and Jurkat T cells. ROS production is
observed in recently extravasated T cells, indicating that oxidative
stress is an early event affecting T cell function in the RA synovial joint.
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Rheumatoid arthritis (RA) is a chronic inflammatory disease of unknown
etiology that primarily affects the joints. Recently, a T cell receptor trans-
genic murine model yielded novel insights. K/BxN TCR transgenic mice
spontaneously develop an autoimmune arthritis that resembles human
RA. Arthritis development depends on the recognition of the ubiqui-
tously expressed glycolytic enzyme GPI by both the transgenic T cells
and B lymphocytes. Here we show that immunization with heterologous
GPI in adjuvant induces a symmetric polyarthritis of the small distal
joints in genetically susceptible mice. The course of GPI-induced arthri-
tis is highly predictable: clinically overt arthritis develops 9–10 days after
immunization, reaches its maximum at D15 and then slowly resolves.
Histologically, the disease is characterized by early synovitis followed by
massive cartilage destruction and erosions of the bones and later reso-
lution of the inflammation, fibrosis, and repair processes. Although anti-
body titers in susceptible and nonsusceptible mouse strains are high,
transfer of purified total IgG of sick mice alone do not transfer disease.
Anyway, antibodies seem to play a major role since Fc-receptor γ-chain
deficient mice develop disease with a much lower frequency and
reduced severity than the wild-type mice. Treatment with a depleting
monoclonal anti-CD4 antibody completely prevents disease. Depletion
of CD4+ T cells during disease leads to a rapid resolution of arthritis.
Therefore, CD4+ T cells are important for both the induction of the
disease and the effector phase. Thus, GPI-induced arthritis in normal
mice bridges the gap between the transgenic K/BxN model and the
highly complex human situation, thereby providing a model in which both
the induction and effector phase of antigen specific arthritis can be dis-
sected, and preventive and therapeutic strategies evaluated.
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Background Myeloid related protein (MRP)8 and MRP14 are
expressed in early monocytes, whereas CD163 is marker for mature
tissue macrophages.
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Objective To analyse macrophage subsets in RA and SpA, and the
effect of infliximab on the synovial infiltration of these subsets.
Methods Paired synovium and synovial fluid (SF) were collected in
20 RA and 30 SpA patients. In nine SpA patients, synovium was also
obtained after 12 weeks of infliximab treatment. The levels of expres-
sion of MRP8, MRP14, CD163 and CD68 were analyzed by immuno-
histochemistry on frozen sections. Levels of MRP8/MRP14 in SF were
determined by ELISA.
Results In inflammatory arthritis, MRP8, MRP14, CD163 and CD68
positive cells were abundant in the lining and sublining layer. The
expression of CD68 and CD163 exhibited a cellular pattern. The
MRP8 and MRP14 expression was characterized by a cellular staining,
with in some samples also an extracellular and perivascular pattern.
Comparing RA and SpA, CD68-positive macrophages were equally
present (lining P = 0.463, sublining P = 0.235), whereas MRP8
expression was higher in the lining of RA synovium (P = 0.025) and
CD163-positive cells were more prominent in SpA synovium (lining
P < 0.001, sublining P = 0.017). No differences for MRP8, MRP14,
CD163 or CD68 were seen between the SpA subgroups. Confirming
that these markers identify different macrophage subsets, the expres-
sion of MRP8 and MRP14 was more reduced after infliximab than
CD163 (MRP8: lining P = 0.038, sublining P = 0.023; MRP14: lining
P = 0.088, sublining P = 0.036; CD163: lining P = 0.119, sublining
P = 0.125). Local secretion of soluble MRP8/MRP14 was evidenced
by high SF levels (RA 24 530 ng/ml, SpA 4152 ng/ml), which were
higher than in serum (RA 20-fold, SpA 6-fold).
Conclusion MRP8/MRP14 and CD163 identify different macrophage
subsets as evidenced by the differential expression in RA versus SpA,
and by the differential effect of infliximab on the synovial expression of
these markers
67
Involvement of SUMO-1 in the regulation of
apoptosis in prosthesis loosening fibroblasts
I Meinecke1, A Wille1, A Cinski1, W Neumann1, B Ink2, R Hay3, 
S Gay4, T Pap1,4
1University Hospital Magdeburg, Germany; 2GSK, London, UK;
3University of St. Andrews, UK; 4University Hospital Zurich,
Switzerland
Arthritis Res Ther 2004 6(Suppl 1):67 (DOI 10.1186/ar1109)
Background Prosthesis loosening fibroblasts (PLF) contribute signifi-
cantly to the pathogenesis of aseptic prosthesis loosening (APL) and
show similarities to rheumatoid arthritis synovial fibroblasts (RA-SF).
Based on data that have linked the increased expression of the small
ubiquitin-like modifier SUMO-1 to the resistance of RA-SF against
apoptosis, we investigated the expression of SUMO-1 in APL and used
gene transfer of the SUMO protease SENP1 to study consequences of
SUMOylation in PLF.
Methods We used in situ hybridization (ISH) to study the expression of
SUMO-1 in APL interface tissues. Quantitative PCR and Western blot
were applied to measure the expression of SUMO-1 in PLF in compari-
son with RA-SF. Confocal microscopy of PLF transfected with GFP-
labeled wild type (wt) or mutant (mt) gene constructs of SENP1 was
performed to investigate the cellular localization of SUMO-1. To study
the functional contribution of SUMO-1 to the apoptosis of PLF,
SENP1wt-, SENP1mt- and mock-transfected PLF were stimulated with
FasL, and apoptosis was determined by a histon fragmentation assay.
Results ISH revealed marked expression of SUMO-1 in all tissues, with
most prominent staining at sites attached to bone. The expression of
SUMO-1 in PLF was comparable with that in RA-SF. Confocal
microscopy revealed localization of SUMO-1 mainly in nuclear PML-
bodies. After transfection of PLF with SENP1, high levels of SENP1
mRNA were measured (up to 472-fold versus endogenous SENP-1).
Transfection of PLF with SENP1wt decreased the nuclear staining for
SUMO-1, and increased significantly FasL-induced apoptosis (155%
versus SENP-1mt). Spontaneous cell death remained unaffected.
Conclusion The data suggest that SUMO-1 is involved in the activa-
tion of PLF and RA-SF by preventing these cells from Fas-induced
apoptosis. The modification of nuclear proteins by SUMO-1 appears to
contribute to the antiapoptotic effects of SUMO-1. By de-conjugating
SUMO-1 from its nuclear substrates, SENP1 can regulate the apop-
totic response of PLF.
Genomics and signal transduction
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Background In rheumatoid arthritis (RA), monocytes are of central
importance in the chronic inflammatory immune response. These cells
may display diagnostic markers and provide insight into pathophysio-
logical pathways in RA.
Objective To identify characteristic expression patterns in rheumatoid
arthritis (RA), highly purified peripheral blood monocytes were investi-
gated.
Methods Monocytes from five normal donors (ND) and six patients
with active RA were purified by erythrocyte lysis and CD14-positive
selection at constant low temperature (4°C) conditions to minimize in
vitro induced artefacts. Gene expression was detected by Affymetrix
HG U133A hybridization. Bioinformatic analysis included MAS5.0
image analysis, statistical methods (t-test; Mann-Whitney) and cluster
analysis (genes@work).
Results Array analysis revealed about 50% present calls in ND or RA
monocytes. MAS5.0 comparison expression analysis revealed 605
genes that were significantly changed in more than 50% of all RA
versus ND pair-wise comparisons. Statistical methods revealed that
260 of these genes were significantly different (P < 0.05). Selection
and reduction by fold changes above 1.6 and statistical methods
reduced the number of differentially expressed genes to 152. This set
of genes is implicated in cellular processes that are involved in cell
communication (cytokines, chemokines and their receptors), intracellu-
lar signalling, transcription, defense response, apoptosis and heat
shock responses. Hierarchical cluster analysis based on these selected
genes separated into two branches, one for ND and one for RA
patients.
Conclusion Gene expression profiling of separated peripheral blood
monocytes identified a characteristic gene pattern that is involved in
the activation of monocytes, and clearly indicates an inflammatory
process in RA. These results will be compared with expression profiles
in other inflammatory rheumatic diseases and further analyzed for domi-
nant pathophysiological pathways in a search for new candidates for
targeted therapy in RA.
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Background In rheumatoid arthritis (RA) macrophages (Mf) play a
pivotal role. They become highly activated in synovitis and at the carti-
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lage–pannus junction. Furthermore, therapeutic neutralization of mole-
cules produced by activated Mf lead to clinical improvement in RA, and
circulating monocytes (MO) of the peripheral blood in patients with RA
spontaneously express proinflammatory genes (IL-1β, IL-6, TNF).
Methods A custom RA-MO cDNA microarray was generated using dif-
ferentially expressed genes obtained from gene subtraction and from
comparative whole genome wide U133A analysis in normal donors,
active and anti-TNF-α treated RA patients. Genes were selected using
MAS 5.0, multtest and PAM. The custom microarray consists of 313
genes including guide dots, and positive (housekeeping genes and
spike controls) and negative controls for image and statistical analysis.
Each probe was spotted in 16 replicates.
Results The RA-MO chipset-II was validated using the following: non-
stimulated and LPS, PMA, Vit.D3+LPS, PMA+LPS stimulated U937
cells; nonstimulated and LPS stimulated healthy donor MO; MO from
normal donors (n = 3) and RA patients before and during anti-TNF-α
treatment (n = 5 each); and synovial tissue from normal individuals
(n = 2) and RA patients (n = 2). Not only LPS/PMA regulated genes
but also RA specific and anti-TNF-α regulated genes were validated. In
addition, we could clarify whether these genes are differentially tran-
scribed only in MO or whether they can also be found in RA tissue Mf.
Our data indicate a high degree of reproducibility that is sufficient for
diagnostic applications and therapy monitoring.
Conclusion The RA-MO chipset-II microarray is competitive and flexi-
ble for enlargement of the number of genes. The current gene selection
will contribute to validating the role of monocytes in disease activity, to
therapeutic interventions, and may improve the knowledge on the regu-
lation of pathways in activated monocytes in chronic inflammation.
70
Reporter cell lines for real-time imaging of NF-κ κB
activation in the arthritic joint
RL Smeets, LAB Joosten, WB van den Berg, FAJ van de Loo
Department of Rheumatology, University Medical Center Nijmegen,
The Netherlands
Arthritis Res Ther 2004 6(Suppl 1):70 (DOI 10.1186/ar1112)
Background Inadequate functioning of NF-κB is implicated in many
diseases, such as rheumatoid arthritis (RA), and increased activation of
NF-κB in synovial tissue precedes the clinical manifestation of experi-
mental arthritis.
Objective The aim of the study was to develop NF-κB reporter cell-
lines that can be used for real-time evaluation of NF-κB activation in
knee joints during experimental arthritis in living animals.
Methods For determination of NF-κB transcription activity, an eukaryotic
expression vector was created containing five tandemly arranged NF-κB
binding sites (5′-GGGACTTTCC-3′) regulating luciferase expression.
Cell lines were selected on stable incorporation of 5 × NF-κB luciferase
and responsiveness was tested toward NF-κB inducing stimuli.
Results These cell-lines, derived from fibroblasts, chondrocytes and
thymocytes, showed good cytokine responsiveness toward IL-1, IL-17,
IL-18, and TNF. We showed that these cells could also be used in in
vitro inhibition assays using cytokine protein antagonist (e.g. IL-1Ra
and IL-18BPc) or RNA interference. By transplanting these cells into
HLA matched recipients we were able to image in real time NF-κB acti-
vation in knee joints of mice with IL-1- or SCW-induced inflammation
using a cooled-charge-coupled device (CCCD) camera. Interestingly,
NF-κB activation was also activated at sites remote from the monokine
or SCW injection sites. Synovial mRNA revealed a striking upregulation
of IL-1 in both SCW challenged and contralateral knee joint. This effect
was confirmed by pretreatment of mice with neutralizing anti-IL-1 Abs,
which markedly prevented the NF-κB activation in the contralateral
naive joints.
Conclusion These reporter cell-lines can be a valuable tool to study
the role of NF-κB activation in arthritis and to evaluate cytokine/NF-κB
based inhibition therapies. Furthermore, we show that local induction of
experimental arthritis results in contralateral NF-κB activation, which is
dependent on IL-1.
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Background Thymosin β4 (Tb4) is a 4.9 kDa ubiquitously expressed
intracellular peptide known to sequester G-actin, with a growing
number of extracellular biological functions. We have shown that oxida-
tion of its single methionine residue at position 6 (Tb4 sulphoxide
[Tb4SO]) gives the peptide potent anti-inflammatory properties. In
addition, Tb4 promotes wound healing in various in vitro and in vivo
models. The mechanism by which Tb4SO exerts its extracellular bio-
logical functions is unknown. Its cell receptor remains unidentified and
intracellular signalling consequences of Tb4SO require elucidation.
Objective The study was conducted to investigate the intracellular sig-
nalling consequences of the addition of Tb4SO to various cell types,
specifically MAP kinase activation.
Methods Cell types used were treated with Tb4SO and lysed using
RIPA buffer. Lysates were run on SDS PAGE, transferred to PVDF
membrane and probed with antiphospho ERK1/2, p38, JNK1/2 or AKT
antibodies. Membranes were then stripped and reprobed with pan-
antibodies to allow normalization of samples.
Results Tb4SO induced the phosphorylation of ERK1/2 in peripheral
blood-derived monocytes in dose-dependent manner. This was inhib-
ited by addition of U0126, an inhibitor of the upstream activator of
ERK1/2, implicating ERK1/2 in Tb4SO-mediated functions in mono-
cytes. Neither p38 MAPK nor JNK1/2 were activated in peripheral
blood monocytes. In peripheral blood-derived macrophages, Tb4SO
induced rapid and marked activation p38 MAPK, pAkt and ERK1/2, but
not of JNK (p-JNK1/2). Interestingly, only JNK1 was activated by
Tb4SO in HeLa cells, and this occurred in a delayed (after 15 min) and
transient manner. Short-term activation of JNKs has previously been
shown to be involved in the upregulation of apoptosis. Preliminary
studies have shown an acceleration in neutrophil but not monocyte/
macrophage apoptosis in response to Tb4SO.
Conclusions These observations suggest that Tb4SO activates
MAPKs and that activation is dependent on cell type, which may in turn
regulate differential functions in these different cell types.
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Background Not all rheumatoid arthritis (RA) patients respond well to
the standard infliximab regimen. No clinical or biological factor that
would allow one to predict response has yet been identified.
Objective The aim of the study was to test whether the –308 G/A
polymorphism in the promoter of the TNF-α gene and the –1082 G/A
polymorphism in the promoter of the IL-10 gene influence response to
infliximab therapy in patients with RA.
Methods We genotyped 85 RA patients for –308TNFalfa polymor-
phism by PCR and subdivided them into group A (A/A or A/G geno-
types) and group B (G/G genotypes). We compared clinical response
to infliximab treatment between the two groups after four infusions,
using the DAS28 index.
Results We found that 47.4% of patients in group A and 79.3% of
patients in group B had DAS28 index improvement greater than 1.2
(P = 0.0075) and that the average DAS28 improvement was 1.12 in
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group A and 2.08 in group B (P = 0.05). IL-10 polymorphism did not
allow us to discriminate between good and poor responders.
Conclusion These data suggest that the –308 A/G and the –308 A/A
TNF-α genotypes predict poor response to infliximab therapy in RA.
–308TNFalfa genotyping might represent an easy tool with which to
predict response to infliximab treatment. Conversely, the IL-10 polymor-
phism did not appear to be useful.
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Background Gene array analyses reflect the molecular complexity in
rheumatoid synovitis. Insufficient knowledge about the majority of differ-
entially regulated genes hampers adequate interpretation.
Objective To unravel this complexity, cell type specific expression pro-
files were applied as baseline information for comparison.
Methods Gene expression profiles were determined by Affymetrix HG-
U133A array hybridization of synovial tissues, sorted blood monocytes,
granulocytes, CD4 and CD8 T cells from up to 10 patients with
rheumatoid arthritis (RA) and 10 normal donors (ND). Primary analysis
was performed using MAS5.0. Tissues were scored according to histo-
logical standards (Krenn, Pathol Res Pract 2002).
Results Compared with ND synovium, 145 genes were differentially
regulated in all, and up to 2681 genes in at least 50% of RA-ND pair-
wise comparisons. Marker genes of isolated cell populations were
defined by absence in more than 70% of other populations and normal
synovial tissue, defining 59, 25 or 110 genes for granulocytes, mono-
cytes or T cells, respectively. Of these markers, 1, 6 or 22 were identi-
fied in more than 50% of RA-ND comparisons for each cell type,
respectively. This reflects the altered cellular composition in synovitis.
Excluding all genes present in normal tissue or any of the purified popu-
lations revealed immunoglobulins as markers of B-cell infiltration.
Conclusion This initial analysis of our approach substantially improved
the quality of array interpretation and allows identification of tissue
associated gene regulation. It helps to identify markers shared between
blood and tissue and may provide candidates for disease classification
and activity scoring.
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Background In Wegener’s granulomatosis (WG) the development of a
generalized vasculitis is based on strong expression of proteinase 3
(PR3) on the surface of neutrophil granulocytes and the appearance of
circulating high-affinity anti-PR3 autoantibodies (PR3-ANCAs) sug-
gesting an antigen-driven B lymphocyte maturation.
Objective In order to analyze mechanisms relevant to the induction of
ANCA, we compared the immunoglobulin heavy chain (VH) gene
repertoire in biopsy specimen of granulomas from two cases of ANCA-
negative localized WG and from two cases of ANCA-positive general-
ized WG with a healthy control.
Methods  Frozen tissue samples were stained for B lymphocytes by
anti-CD20 APAAP. DNA was prepared, purified and subjected to a
PCR with individual VH primers matching to the families VH1–VH6 and
a JH consensus primer. After bacterial subcloning PCR products were
sequenced and characterized for gene usage and mutational pattern.
Results Immunohistology revealed lymphoid infiltrates within typical
WG granulomas containing more than 30% B cells, which is sugges-
tive of germinal center formation (Fig. 1). One hundred and fifty differ-
ently rearranged VH genes from WG tissues were characterized and
compared with 84 VH genes from peripheral blood of a healthy donor.
The mutation frequency as well as the ratio of amino acid replacement
to silent mutations indicate an antigen-driven selection of antibodies
within such germinal center-like regions of the granuloma in WG and
differ significantly from the healthy control. The VH genes in WG
revealed both striking similarities to published PR3-ANCA-encoding
genes as well as to VH genes from Staphylococcus aureus superanti-
gen-affine B cells. Furthermore, 50% of mutations within the binding-
site coding regions led to negatively charged amino acids that favour
affinity to the positively charged PR3.
Conclusion  In WG a subset of autoreactive PR3-producing B cells
may be induced to produce PR3-ANCA within granulomatous lesions
after Staphylococcus aureus B-cell superantigen stimulation. Selected
B cells undergo affinity maturation and differentiate into plasma cells
that produce high levels of circulating ANCAs, which are involved in
the pathogenesis of the systemic vasculitis.
Acknowledgement  This work is supported by the Deutsche
Forschungsgemeinschaft (Sonderforschungsbereich 367, A11) and by
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Introduction Toll-like receptors (TLRs) play an important role in the
innate and adaptive immune response. TLR4 is the most thoroughly
studied member of this receptor family and interacts with endogenous
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Figure 1
CD20 staining of a cryosection from an endonasal Wegener
granuloma.S25
ligands, which are abundantly present in the synovial joint during
rheumatoid arthritis (RA).
Objective The aim of the present study was to analyze the relationship
between the TLR4 Asp299Gly (896A>G) polymorphism and RA suscepti-
bility, disease phenotype and outcome over a 6-year period of the disease.
Methods Genotyping was performed on RA patients from an early RA
inception cohort. Healthy controls consisted of healthy blood donors.
To assess the influence of the TLR4 variant on disease phenotype,
course and outcome, we compared prospectively collected disease
activity and outcome parameters of patients with and without the
variant TLR4 allele. TLR4 genotyping of the A>G polymorphism at
position 896 of the TLR4 gene was performed using RFLP.
Results in 282 RA patients and 314 healthy individuals we found that
the frequency of the TLR4 Asp299Gly polymorphism was significantly
lower among RA patients (10.6%) than among controls (17.2%;
P = 0.02). To analyze potential differences in disease phenotype,
severity and outcome 30 RA patients heterozygous for the TLR4 variant
were compared with 252 RA patients possessing two wild-type alleles.
Apart from the higher DAS at baseline (6.1 versus 5.4; P = 0.01), no
other differences in phenotype, severity or outcome of RA were
detected between both groups.
Discussion Here we demonstrate a link between RA disease suscepti-
bility and the TLR4 polymorphism in a large set of RA patients and
healthy individuals. Furthermore, we show that the TLR4 polymorphism
might be important in the onset of disease but does not seem to play a
role in disease outcome.
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Background Sacroiliitis (SI) is a common extraintestinal manifestation
of Crohn’s disease (CD). In contrast to idiopathic ankylosing spondyli-
tis (AS), its association with HLA-B27 is less evident. Mutations in the
CARD15 gene are recently identified as susceptiblity genes for CD.
The CARD15 gene encodes the intracellular NOD2 receptor and
should play an important role in innate immunity. Studies on associated
disease phenotypes revealed a predisposition for ileal localization, early
onset of disease, familial cases and fibrostenosing disease. We
recently described a higher prevalence of CARD15 variants in a sub-
group of spondyloarthropathy patients with chronic gut inflammation,
which are prone to evolution to CD.
Background The present study evaluated whether CARD15 polymor-
phisms are associated with sacroiliitis in patients with CD.
Methods One hundred and two consecutive CD patients were clini-
cally evaluated by a rheumatologist. Radiographs of sacroiliac joints
were performed and blindly scored by two investigators. RFLP-PCR
technique was used to genotype all patients for three single nucleotide
polymorphisms in the CARD15 gene. Every SNP was verified by direct
sequencing. HLA-B27 phenotype was determined.
Results Radiological evidence of SI with or without AS was present in
23 patients (23%). Of patients with SI 78% carried a CARD15 variant,
versus 48% of patients without SI (P = 0.011; OR 3.8, 95% CI
1.3–11.5). A logistic regression analysis with SI as dependent variable
and CARD15, HLA-B27, famililial cases, need for resection surgery,
age of diagnosis and ileal disease as covariates showed that only car-
riage of CARD15 variants was a significant predictor of SI (P = 0.035).
Conclusion This result suggests that carriage of CARD15 variants is a
genetic marker for CD related SI, independent of HLA-B27 or other
CARD15 related phenotypes.
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The molecular pathogenesis of rheumatoid arthritis (RA) is still poorly
understood and its clinical course can vary widely. In a recent report
we noted heterogeneity in global gene expression signatures between
synovial tissue specimens from different patients with RA. The results
of the present study support the view that clinically diagnosed RA is a
heterogeneous disease that is featured not only at the whole synovial
tissue level but also at the level of FLS cultured from those tissues.
One of the most impressive features of our 24k cDNA microarray profil-
ing studies is the clear correlation of the FLS phenotype with that of
paired synovial tissue from which the cells were derived. One class of
FLS is tightly related to the presence of lymphocytes in the lesions
whereas the other class of FLS suggests that synoviocyte-mediated
invasion appears to be less dependent on infiltrating immune cells.
Clearly, the list of genes that are differentially expressed between the
FLS subgroups facilitates our understanding of the pathophysiology of
the distinct groups of rheumatoid FLS. These data reveal features of
fibrosis as the hallmark of FLS derived from a high inflammatory lesion,
whereas FLS that are characterized by deregulated growth appear to
constitute a characteristic feature of low inflammatory tissues. These
data support the notion that heterogeneity between synovial tissues is
reflected in the FLS as a stable trait and provide a molecular basis for
the well recognized but as yet poorly understood heterogeneity in RA.
Gene therapy
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Background Salivary glands (SGs) provide a novel target site at which
gene transfer can be accomplished in a minimally invasive manner [1].
SGs are also capable of producing large amounts of proteins, and
human SGs are well encapsulated, a circumstance likely to minimize
the undesirable access of administered vectors and transgenes to
other tissues [2]. Previous studies have indicated that intravenous,
intramuscular and intranasal administration of rAAV2 vectors induce
relatively mild host immune responses.
Objective The aim of the study was to examine the effects on immune
responsiveness of rAAV2 vector delivery into SGs.
Methods  The main excretory ducts of the submandibular glands of
Balb/c mice were cannulated and vectors administered by retrograde
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infusion [1]. On day 0 we delivered a rAAV2 encoding β-galactosidase
or saline (control) to adult mice. On day 28, we administered a second
rAAV2 vector encoding either human erythropoeitin (Epo) or human
growth hormone to one-third of each group. Immune activities were eval-
uated in saliva, serum, SGs and spleens collected at different times.
Results Vector delivery had little effect on salivary flow rates at all time
points studied. Histological examination of SGs on day 1 did not indi-
cate any significant inflammatory cell infiltration due to rAAV2 vectors.
Ex vivo stimulation, with rAAV2, of splenocytes on days 28 and 56
resulted in elevated interferon-γ levels in culture media from rAAV2-
administered mice, but not from control mice. Significant titers of neu-
tralizing antibodies to rAAV2 were detected in serum, with generally
lower levels found in saliva. We were unable to observe transduction of
SG cells by rAAV2Epo in mice previously infected with rAAV2LacZ (i.e.
no elevations in hematocrit [Hct] and serum Epo levels were seen in the
virus re-administration group). Conversely, we found significant eleva-
tions in Hct and serum Epo levels in mice previously administered saline.
Conclusion We conclude that after a single administration of rAAV2 to
murine SGs there is no significant innate immune response. However,
we observe a modest adaptive immune response that abrogates the
efficacy of additional rAAV2administration.
Acknowledgement MRK and PPT are supported by the Dutch Arthritis
Foundation NR 02-1-302.
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Objective Adeno-associated virus (AAV) is a very promising vector for
gene therapy in RA. Although an increasing number of AAV serotypes
have been identified, all studies so far have been performed with
serotype 2. The aim of this study was to compare the transduction effi-
ciency of five different AAV serotypes (AAV1–AAV5) encoding reporter
genes, the murine secreted alkaline phosphatase (mSEAP) or the
E. coli β-galactosidase (beta-Gal), in two different animal models of
arthritis.
Methods AAV1–AAV5 containing the gene for beta-Gal were injected
into the right ankle joints of rats with adjuvant arthritis (AA) on day 12
after adjuvant immunization. Joints were collected 2 weeks after injec-
tion. The number of viral genomic copies in the joint was determined by
qPCR. For detection of LacZ transcription in joints and organs,
RT-PCR was used. Beta-Gal expression was analyzed by direct in situ
staining of frozen sections, quantified by digital image analysis. In mice
with collagen-induced arthritis (CIA), AAV1, 2 and 5 constructs encod-
ing the mSEAP gene were injected into the left knee joint 32 days fol-
lowing arthritis induction. Transgene expression was analyzed by
chemiluminescence in sera and culture medium conditioned by the
joint tissues at different time points.
Results The greatest number of viral genomic copies was detected
using AAV5. This was confirmed by in situ beta-Gal staining. RT-PCR
proved the presence of LacZ mRNA in injected joints, but not in any of
the organs tested. In the CIA mice model AAV5 also had the best
transduction efficiency. Transgene expression was detectable in sera
and patellae 1 week after joint injection, increased over time, and
remained at plateau levels for at least 1 month.
Conclusion In vivo gene transfer with AAV5 is far more efficient than
with other serotypes. Local AAV-mediated gene therapy in RA could be
improved by using AAV5.
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Background Rheumatoid arthritis is characterized by an acute phase
response of the liver. IL-6 is produced in the inflamed joint and high levels
are found in the circulation. IL-6 is a potent inducer of acute-phase pro-
teins (APP) in hepatocytes via its signal transducer gp130 by the activa-
tion of the signal transducer and activator of transcription (STAT)-3.
Objective The aim of the study was to determine the effect of adenovi-
ral gene transfer of SOCS-3, the inhibitor of STAT3 activation, on colla-
gen-induced arthritis (CIA).
Methods Livers were dissected, and activation of STATs was analyzed
by Western blot and gene expression by RT-PCR. A replication incom-
petent adenovirus containing the gene of murine SOCS-3 was con-
structed. Mice received 3 × 10e8 ffu of Ad5.CMV.mSOCS3 or control
viruses intravenously before onset of arthritis. The effect of SOCS gene
transfer on liver function was studied in zymosan-induced gonarthritis
(ZIA) and the therapeutic effect in CIA.
Results Induction of ZIA in the knee joints of mice caused a rapid
(within 5 hours) activation of STAT3 but not STAT1 in the liver. The
activation of STAT3 was IL-6 dependent, as shown using IL-6 gene
knockout mice. Intravenous injection of Ad5.CMV.mSOCS3 24 hours
before induction of ZIA prevented STAT3 activation and markedly
reduced serum amyloid A (SAA)-1 gene expression in the liver. Control
virus treatment did not inhibit STAT3 activation in the liver. Overexpres-
sion of SOCS-3 did not affect Erk activation, confirming selectivity for
the STAT signaling pathway. Treatment of DBA1/j mice with
Ad5.CMV.mSOCS3 virus after immunization ameliorated CIA, and
reduced serum TNF-α levels accompanied this effect. SOCS-3 treat-
ment had no effect on the circulating levels of total IgG, IgG2a and IgG1
anti-collagen type II antibodies.
Conclusion Inhibition of STAT-mediated signaling via SOCS-3 adenovi-
ral gene transfer in the liver markedly ameliorated CIA. This suggests that
the IL-6 mediated liver response modulates the development of arthritis.
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Background and Objective Novel cytokines have been identified by
structural homology to IL-10. Among them, IL-22 showed a 25% amino
acid identity with IL-10 and shared a common receptor β-subunit. The
expression profile suggested involvement in the immune response in
vivo. The present work evaluates the role of IL-22 in arthritis, examining
the effects of systemic murine IL-22 adenoviral-mediated overexpression
(Ad-mIL-22) in the collagen-induced arthritis (CIA) DBA1 mouse model.
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Method Human rheumatoid arthritis (RA) synovial fibroblast (SF) were
infected  in vitro with increasing doses of Ad-mIL-22 (0-25 MOI).
Cytokine secretion was assessed in supernatant using a specific
ELISA. Therapeutic efficiency of mIL-22 overexpression achieved by
intravenous injection of Ad-mIL22 (5 × 109 pfu) after the onset of CIA
was assessed. A group injected with a nonrelevant adenoviral vector
(Ad-LacZ) was used as a control. Radiological and histological analy-
ses were performed at day 47. Systemic expression of mIL-22 was
assessed by ELISA.
Results After confirmation that human RA-SF infected with increasing
doses of Ad-mIL-22 expressed high levels of mIL-22 transgene, we
demonstrated that the intravenous injection of Ad-mIL-22 in DBA1
mice significantly reduced clinical, radiological and histological scores.
By the end of the experiment, the number of arthritic paws was
decreased by 70% in the Ad-mIL-22-treated group as compared with
controls (P < 0,0001). Ad-mIL-22 resulted in the complete protection
as compared with control vector up to 20 days after treatment. Maximal
paw widths reached during the course of the disease were, respec-
tively, 1.95 × 0.08 versus 2.76 × 0.60 mm (P = 0.024). Both radiologi-
cal and histological scores were found to correlate well with clinical
observations. Systemic levels of mIL-22 reached 14.2 ± 9.5 ng/ml
4 days after gene transfer, then decreased to 2.4 ± 0.9 ng/ml by day 8
and remained stable until day 21.
Conclusion Our data support that IL-22 may have antiarthritic proper-
ties. The molecular mechanisms responsible for this observation are
under investigation.
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Objectives Electrotransfer (ET) was used to administer transgenes
encoding three hTNF-α soluble receptor-I variants. Electrotransfer
parameters and therapeutic effect in collagen-induced arthritis (CIA) in
mice were studied.
Methods Plasmids pCOR(hTNFRIs)1, pCORhTNFRIs/mIgG1,
pCOR(hTNFRIs)2, encoding a monomeric, a chimeric or a dimeric form
of hTNFRI, respectively, were used. Electrotransfer was performed by
plasmids injection and electric pulses in muscle. hTNFRIs concentra-
tions were determined by ELISA. PCR was performed on genomic
DNA from various mouse organs to detect the plasmid. CIA was
induced by immunization of DBA/1 mice with collagen II in adjuvant.
Results ET of the three plasmids (1–15 µg) allowed hTNFRI produc-
tion in sera and muscle after 10 days. This expression was dependent
on the dose of plasmid. Local expression in the muscle lasted for at
least 6 months. Systemic expression in the serum was detectable right
from 1 µg for the hTNFRIs/mIgG1 form. It lasted for at least 6 months
for the hTNFRIs/mIgG1 form, whereas expression was shorter for the
two other forms (3 weeks). No plasmid DNA was found in the organs
distant from the injected muscle (liver, spleen, kidney, gonads, heart,
lung brain and distant muscle). ET of 50 µg pCOR/sTNFRI/IgG1
plasmid at the onset of clinical disease induced a clear-cut decrease in
clinical signs of arthritis. The dimeric form was also efficient
(P = 0.0378) although the effect was weaker than with the fusion
protein. The monomeric form had no effect on arthritides.
Conclusion Intramuscular ET of plasmids encoding the three forms of
hTNFRIs leads to a long-term secretion of hTNFRIs in vivo. CIA is effi-
ciently inhibited when ET of plasmids encoding either the chimera or
the dimeric hTNFRIs was performed at the onset of the disease.
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Background Gene therapy studies in experimental models of arthri-
tis have demonstrated effective treatment with a variety of immuno-
suppresive and proapoptotic genes using in vivo and  ex vivo
strategies. Regardless of which approaches are developed for clini-
cal application of gene therapy, we believe that it is imperative that
expression of a therapeutic gene is regulated so that levels of
expression are controlled and can be downregulated in the event of
adverse effects.
Objective We previously constructed an autoregulatory self-contained
plasmid vector pGTRTL in which gene expression is induced with doxy-
cycline (Dox). Expression kinetics of luciferase from this vector have
been characterized in vitro. In this investigation we examined the
dynamics of luciferase expression from pGTRTL delivered in vivo to
DBA/1 mice. Therapeutic effect of a small dimeric TNFR2 molecule
(dTNFR) expressed constitutively from the vector pcdTNFR and regu-
lated from the vector pGTRTT was compared in DBA/1 mice with
established collagen-induced arthritis (CIA).
Methods Plasmid DNA was administered to naïve or arthritic mice by
intramuscular injection combined with electroporation. Gene expres-
sion from regulated vectors was induced with Dox administered in
drinking water. The degree of arthritis was scored every 2–3 days, and
at the end of the experiment serum immunoglobulin levels and cytokine
release from lymph node cells was measured.
Results The results show efficient regulation of luciferase expression
from pGTRTL in vivo. Expression of dTNFR from constitutive or regu-
lated expression vectors in mice with established CIA was therapeutic
(Fig. 1), but was dependent upon the level of disease activity when
treatment was initiated.
Conclusion Improved pharmacologically regulated vectors could be
developed for clinical application. There is also scope to utilize disease-
responsive vectors that contain DNA binding motifs that respond to
transcription factors upregulated in arthritic joints.
Acknowledgement Funded by the Arthritis Research Campaign UK.
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Figure 1
Progression of CIA in mice treated with dTNFR expressed
constitutively from pcdTNFR (a) and induced from pGTRTT (b).S28
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Objectives We performed here a detailed analysis of the newly devel-
oping immune systems in patients treated with immune ablation and
subsequent autologous stem cell transplantation (ASCT) for severe
autoimmune diseases.
Methods Peripheral blood lymphocytes were analyzed using flow
cytometry, including assessment of TCR-Vβ repertoire of Th cells.
Thymic activity was determined by measuring T-cell receptor excision
circles (TRECs) in distinct peripheral blood Th cell subsets by quantita-
tive RT-PCR analysis.
Results Twelve patients, with median follow up of 40 months, were
included in the trial thus far: polychonditis (n = 1), systemic lupus ery-
thematosus (SLE; n = 6), systemic sclerosis (SSc; n = 3), panniculitis
(n = 1) and MS (n = 1). Clinical remission has been achieved in seven
patients: polychondritis (n = 1), SLE (n = 5) and MS (n = 1). We
observed progress of disease in patients with SSc and panniculitis. In
one patient SLE reactivated 17 months after ASCT. In all responding
patients no autoreactive Th cells could be detected, and serological
remission has been achieved. Lymphocyte compartments reconstituted
functionally in all patients as shown by the reappearance and persis-
tence of naïve T cells with high levels of TRECs and restored diversity
of the T cell receptor repertoire. Reconstituting B cells were found to
be of naïve phenotype. Although we observed similar kinetics of lym-
phocyte repopulation in the nonresponding SSc patients, autoantibody
titres (ANA, SCL70) were not affected by conditioning.
Conclusion The newly generated immune system in responding
patients is tolerant to rheumatic autoantigens and able to react to
pathogens. We conclude that in successfully treated patients autore-
active memory and effector lymphocytes have been eliminated effi-
ciently. Our data demonstrate that ASCT can induce stable long-term
clinical and serological remission in patients with severe, standard-
therapy refractory autoimmune diseases.
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Objective Increased osteoclast activity is a key factor for bone loss in
rheumatoid arthritis (RA). This suggests that osteoclast-targeted thera-
pies could effectively prevent skeletal damage in RA. Zoledronic acid
(ZA) is one of the most potent agents to block osteoclast function. We
therefore investigated whether ZA can inhibit inflammatory bone loss.
Methods Human TNF transgenic (hTNFtg) mice, which develop severe
destructive arthritis as well as osteoporosis, were treated with phos-
phate-buffered saline, single or repeated doses of ZA, calcitonin or
anti-TNF at the onset of arthritis.
Results Synovial inflammation was not affected by ZA. In contrast,
bone erosion was retarded by single administration (–60%) and almost
completely blocked by repeated administration (–95%) of ZA. Carti-
lage damage was partly inhibited (–40%), and synovial osteoclast
counts were significantly reduced upon ZA treatment. Systemic bone
mass dramatically increased in hTNFtg mice upon ZA administration,
which was due to an increase of trabecular number and connectivity. In
addition, bone resorption parameters were significantly lowered after
ZA. Calcitonin had no effect on synovial inflammation, bone erosions,
cartilage damage, or systemic bone mass. Anti-TNF entirely blocked
synovial inflammation, bone erosion, synovial osteoclast formation and
cartilage damage, but had only minor effects on systemic bone mass.
Conclusion ZA appears an effective tool with which to protect bone
from arthritic damage. In addition to anti-inflammatory drug therapy,
modern bisphosphonates are promising candidates to maintain joint
integrity and to reverse systemic bone loss in arthritis.
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Background Effective amelioration of symptoms and induction of
remission are goals in treatment of rheumatoid arthritis (RA).
Objectives Data from a Phase II study for RA treatment with abatacept,
a selective co-stimulation modulator, showing induction of remission
(DAS-28 score <2.6) are presented.
Methods Patients on background methotrexate (MTX) who met ACR
criteria for active RA with ≥10 swollen joints (66 joint count) and
≥12 tender joints (68 joint count) were randomly assigned to receive
10 mg/kg abatacept (n = 115) or placebo (n = 119) treatment for
1 year. DAS-28 scores and serum cytokine levels were assessed at
days 1, 90, 180 and 360.
Results Abatacept-treated patients showed a progressive increase in
remission rates up to 1 year (analysis not prespecified) compared with
placebo (P < 0.001; Fig. 1). Abatacept treatment also decreased serum
levels of proinflammatory cytokines. In particular, levels of serum IL-6, a
multifunctional cytokine that contributes both to acute phase response
and to pathological B cell activation, were reduced by 67% at 180 days
and by 73% at 360 days (P < 0.05). Placebo-treated patients showed
no reduction. Abatacept was generally safe and well tolerated.
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Figure 1
Abatacept increases the remission rate in RA patients refractory to
MTX treatment. Means and 95% confidence intervals are shown.
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Conclusions In patients with active RA who were receiving MTX, abat-
acept treatment significantly improved RA symptoms and produced a
progressive increase in remission rates for over one-third of the treat-
ment group, which was sustained at 1 year. In addition, abatacept
decreased serum IL-6 levels. The results of this phase II study suggest
that abatacept may have potential as therapy for patients with active
RA despite MTX treatment.
Acknowledgement Study supported by Bristol-Myers Squibb.
87
Multidrug resistance proteins and DMARD efficacy in
rheumatoid arthritis
G Jansen1, R Oerlemans1, J van der Heijden1, WF Lems1, 
GL Scheffer2, RJ Scheper2, BAC Dijkmans1
1Department of Rheumatology, VU Medical Center, Amsterdam, The
Netherlands; 2Department of Pathology, VU Medical Center,
Amsterdam, The Netherlands
Arthritis Res Ther 2004 6(Suppl 1):87 (DOI 10.1186/ar1129)
Background Upregulation of drug efflux pumps belonging to the family
of ATP-binding cassette (ABC) transporters can confer loss of effi-
cacy/resistance to muliple cytostatic drugs, a phenotype referred to as
multidrug resistance (MDR). In clinical rheumatology practice, loss of
efficacy of disease-modifying antirheumatic drugs (DMARDs) is
observed following long-term treatment of rheumatoid arthritis (RA)
patients. Whether loss of efficacy/resistance to DMARDs and cytosta-
tic drugs share common molecular mechanisms is not known.
Objective The aim of this study was to delineate the potential role of
MDR proteins in the loss of efficacy/resistance to DMARDs.
Methods In vitro model systems of human T cells and monocytic/
macrophage cell lines were used to provoke resistance to the DMARD
sulfasalazine (SSZ). SSZ-resistant cell lines, as well as macrophages
from RA patients and healthy controls, were characterized for expres-
sion of MDR proteins.
Results Development of SSZ resistance in T cells and monocytic/
macrophage cell lines was accompanied by a marked induction of the
MDR protein ABCG2. Of note, SSZ-resistant cells displayed cross-
resistance to methotrexate, but showed enhanced sensitivity to gluco-
corticoids (prednisone, dexamethasone). Immunohistochemical studies
revealed increased expression of MDR proteins in macrophages from
RA patients as compared with controls.
Conclusion These results suggest that MDR proteins, originally identi-
fied for their role in resistance to cytostatic drugs, could also be involved
in DMARD resistance [1]. Beyond this, resistance to one particular
DMARD can influence the sensitivity to other antirheumatic drugs.
Acknowledgement Supported by a grant (NRF 03-40I) from the
Dutch Arthritis Association.
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According to the current view, chronic AID are driven by the continu-
ous activation of autoreactive B and T lymphocytes. However, despite
the use of potent immunosuppressive drugs, these patients exhibit con-
tinued autoantibody production, which often contributes to progression
of the AID. To elucidate this problem, we analyzed the lifespan of cells
secreting (auto)antibodies (Ab) in NZB/W mice. The number of
Ab-secreting cells in splenic tissue increased from ages 1 to 5 months
and became stable thereafter. Later, some 60% of the total Ab-secret-
ing cell compartment consisted of dividing, short-lived plasmablasts
(SLPB), whereas 40% consisted of nondividing, long-lived plasma cells
(LLPC) with a half-life of more than 6 months. Although high-dose
cyclophosphamide eliminated SLPB, LLPC survived and continued to
produce (auto)Ab. This explains why treatment with cyclophosphamide
(CY) does not result in the complete disappearance of antinuclear Ab.
Pathogenic anti-dsDNA Ab usually vanish after this treatment, indicat-
ing that they are generated by proliferating SLPB. However, anti-
dsDNA Ab can be resistant to CY in refractory SLE.
We treated six refractory SLE patients by autologous stem cell trans-
plantation (ASCT) using CY and ATG as the mobilization regimen.
ASCT was performed using purified CD34+ stem cells. The patients
have now been followed for 5–70 months. Initially, persistent anti-
dsDNA disappeared within 3 months. Likewise, the ANA became nega-
tive except in one case. That patient continued to exhibit anti-Ro/SSA
and anti-La/SSB, the titers of which decreased continuously and were
undetectable after 17 months. This emphasizes the enormous lifespan
of residual plasma cells after interrupting the supply of new cells from
the dividing SLPB compartment.
In conclusion, the aforementioned ASCT protocol can lead to depletion
of autoreactive LLPC. Since ASCT may not always be able to eliminate
autoreactive LLPC, these cells are potential targets for autoimmune
disease therapy.
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Background Combining anticytokine treatment with a T-cell directed
agent such as cyclosporine A (CsA) may rescue patients refractory to
anti-TNF treatment. We performed an open label, pilot study to explore
the safety and initial efficacy of a triple therapeutic regimen with anti-
TNF, methotrexate (MTX) and CsA.
Methods Nineteen patients with treatment-resistant RA have been
enrolled. Patients had considerable residual disease activity (mean
DAS-28 6.8, 4.5–8.6), although they had received a mean of
16.8 infliximab infusions (range 6–23) and adequate dose adjustments
of both infliximab (mean dose 4.2 mg/kg q6w) and MTX (mean dose
17.1 mg/week). CsA (mean dose of 2.7 mg/kg per day, range 1.6–3.2)
was added to a stable therapeutic regimen. Clinical evaluation of
disease activity and treatment side effects was performed before each
infliximab infusion. Disease activity was evaluated according to DAS-28
index. Primary end-points were treatment safety profile and efficacy
according to the EULAR response criteria. Peripheral blood monocytes
(PBMCs) were collected from five patients at baseline and after
12 weeks, and were assessed for markers of activation (CD25 expres-
sion) by FACS analysis, with or without activation with PHA.
Results Sixteen patients completed 12 weeks of triple therapy. Three
patients discontinued treatment because of adverse events: one for
pneumonia, one for lymph node tuberculosis and one for gastrointesti-
nal discomfort. Seven out of 16 patients (43.7%) achieved moderate
response according to the EULAR response criteria. Statistically signif-
icant improvements in the mean values of tender joints (from 18.5 to
13.1; P = 0.04), swollen joints (from 18.6 to 12.1; P = 0.004), HAQ
(from 1.2 to 0.7; P = 0.01), patients’ global assessment (from 67 to 46;
P = 0.02) and pain (from 64 to 42; P = 0.04) were identified in those
16 patients. CD25 expression both in unstimulated and in PHA stimu-
lated PBMCs was reduced (37 ± 34% to 15 ± 10%, and 50 ± 15% to
29 ± 20%, respectively).
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Conclusion In this preliminary report, addition of CsA to a maximum
combination therapy of anti-TNF and MTX was well tolerated. Infectious
complications that occurred underscore the importance of close follow
up of patients on combined immunosuppressive therapy. Longer follow
up is required to investigate further the safety and initial efficacy of this
regimen.
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Background TNF has been reported to decrease endothelium depen-
dent vasodilatation and promote atherosclerosis. However, recent data
suggest that TNF may also increase the production of nitric oxide
(NOx) by blood vessels, suggesting a more complex effect of this
cytokine. To explore this further, we examined the effect of anti-TNF
agents on flow-mediated vasodilatation (FMD) as well as common
carotid intima–media thickness (IMT) in RA patients.
Methods Two groups of rheumatoid arthritis (RA) patients were
studied. In the first, six patients were treated for the first time with a
triple DMARD combination (methotrexate, hydroxychloroquine and sul-
phasalazine) because of highly active disease (mean DAS-28 6.1). In
the second group 12 patients with active disease (mean DAS-28 6.1),
despite treatment with DMARDs (methotrexate or leflunomide with or
without corticosteroids), were started on anti-TNF agents. Patients
were assessed by high-resolution ultrasound for CC-IMT, FMD (per-
centage of increase in flow-mediated vasodilatation) of the brachial
artery at baseline and after 12 weeks of treatment. RA disease activity
was assessed using the DAS-28, ESR and CRP at the same time
points. Based on the DAS-28, patients were classified as good, moder-
ate or nonresponders. Plasma NOx levels will be measured by the mod-
ified Griess reaction.
Results Two patients in the first group (33%) and six in the second
(50%) had a moderate EULAR response. In both groups moderate
improvements in the mean ESR (from 60 ± 39 to 50 ± 27 and from
38 ± 19 to 34 ± 24, respectively) and CRP (from 1.3 ± 1.3 to 1 ± 0.3
and from 3.7 ± 3.7 to 2.3 ± 2.8, respectively) were found, which were
not significant. Although FMD tended to improve in patients in the first
group (from 9.2 ± 6.4% to 12.3 ± 4.9%; P = 0.11) between baseline
and week 12, patients in the second group remained stable (from
9.5 ± 7.2 to 7.9 ± 5.4; P = 0.49). CC-IMT increased by 6.4%
(0.76 mm to 0.80 mm) in the first group whereas it decreased by 3%
(from 0.65 mm to 0.63 mm) in patients on anti-TNF agents. The effect
on CC-IMT was even greater (from 0.61-mm to 0.53-mm; P = 0.08) in
patients on anti-TNF agents and absence of other risk factors for ather-
osclerosis (e.g. obesity, hypertension or hyperlipidemia). Measurement
of plasma NOx levels is in progress.
Conclusions In this pilot study in patients with highly active RA, mod-
erate improvement in disease activity after anti-TNF therapy did not uni-
formly improve FMD. This may reflect suboptimal control of disease
activity or decrease in TNF-dependent NO production.
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Background In patients with rheumatoid arthritis (RA), inflammation,
dysregulated Epstein–Barr virus (EBV) infection and immunosuppres-
sive therapy may contribute to increased risk for developing lymphoma.
We have shown that EBV load in peripheral blood mononuclear cells
(PBLs) is 10-fold higher in RA patients (16 copies/500 ng DNA) than
in normal controls (1.9 copies/500 ng DNA). EBV load in RA patients
is similar to that in healthy transplant recipients and much lower than in
symptomatic EBV-infected transplant recipients with lymphoprolifera-
tive disease (>500 copies/500 ng DNA).
Objectives We monitored EBV load in RA patients’ PBLs to evaluate
how it was influenced by methotrexate and infliximab, and to detect
lymphoma development.
Methods A total of 221 patients fulfilling the 1987 ACR criteria for RA
and 100 healthy controls were studied. Of these 221 patients, 88 were
followed for 1–4 years: 19 received only methotrexate (eight were
included in the study before introduction of methotrexate), eight received
only infliximab, and 61 received both methotrexate and infliximab. A 214
base-pair fragment from the EBV genome first internal repeat (IR1) was
amplified by quantitative real-time PCR to evaluate EBV DNA load.
Results EBV load decreased dramatically in most patients right after intro-
duction of methotrexate and kept decreasing thereafter. In patients receiv-
ing infliximab and methotrexate, three patterns of EBV load evolution were
observed: stable, decreasing and variable. Patients with only infliximab had
either stable or decreasing EBV loads. Although an increase in EBV load
was observed in a few patients, none of them reached the
500 copies/500 ng level and no patient developed lymphoma.
Conclusions Methotrexate and infliximab do not seem to increase EBV
load in patients with RA.
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Objective The aim of the study was to determine whether a new
method, based on intrapatient comparisons between estimated rates of
prediagnosis radiological progression and subsequent progression,
can be used to assess the efficacy of commonly used disease-modify-
ing antirheumatic drugs (DMARDs) in a longitudinal early rheumatoid
arthritis (RA) inception cohort.
Methods We analyzed clinical data and radiographs from 149 newly
diagnosed RA patients. Four groups were chosen: patients treated
with methotrexate (MTX, n = 56), sulfasalazine (SSZ, n = 55) and aura-
nofin (AUR, n = 19), and a control group of patients who had changed
therapy twice during the first 2 years after diagnosis and whom we pre-
viously presented as a group of poor responders with persistent clinical
activity (control, n = 19). Radiographs were quantified by an experi-
enced reader using Larsen Erosion Score and the ‘X-RayRheuma-
Coach’ software. The rate of prediagnosis radiological progression per
time was estimated by taking the first onset of RA symptoms as the
starting date for radiographic damage.
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Results The mean disease duration from onset of symptoms until diag-
nosis and DMARD institution was 6.7 ± 3.6 months. The mean baseline
Larsen Score was 13.2 ± 9.3, resulting in an estimated prediagnosis
progression rate of 23.6 ± 16.7 Larsen Score units/year. In the control
group and in the patients receiving AUR, radiological progression after
diagnosis was similar to the predicted progression based on the esti-
mated prediagnosis progression rates. In patients for whom MTX or
SSZ was the first-line therapy, a marked (P < 0.001) reduction in radi-
ographic progression in the first year after treatment initiation was seen
compared with prediagnosis progression.
Conclusions Prediagnosis rates of radiological progression can be
used quantitatively to obtain important information on the potential effi-
cacy of DMARDs, and indicate that MTX and SSZ, but not AUR, signif-
icantly retard radiographic damage in the first year after diagnosis.
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Background Skin lesions refractory to treatment are a source of mor-
bidity in patients with scleroderma (CREST) and may result in amputa-
tion. No established DMARD is available for this disorder.
Objective The aim was to report the effect of infliximab in combination
with methotrexate (MTX) on refractory skin lesions in a 46-year-old
woman with scleroderma (CREST).
Case report In 1991, the patient was diagnosed with scleroderma
(CREST). Despite several treatments (initially D-penicillamine and
colchicine, subsequently MTX, colchicine and misoprostol), she devel-
oped severe digital ulcerations, resulting in multiple amputations with
difficult wound healing afterward. Since 1999, she was treated with
MTX, colchicine and alprostadil. In August 2002 she developed necro-
sis at the fingertip of digit IV right. Despite hyperbaric oxygen treatment
and pulse therapy with corticosteroids, the necrosis worsened. There-
fore, infliximab (3 mg/kg iv at weeks 0, 2 and 6, and every 8 weeks
thereafter) combined with MTX (10 mg/w im) was started. The patient
also had ulcerations at digit II left and at the knees, and suffered from
severe Raynaud’s attacks. After the second infusion, the ulcerations
started to heal. Although an amputation of distal phalanx of digit IV
could not be avoided, infliximab was continued. The amputation wound
healed quickly, the ulcerations became considerably smaller, and she
developed no new skin lesions. The inflammatory parameters remained
stable and her general condition improved; she gained weight (6 kg),
had less pain in the fingers and fewer Raynaud’s attacks, and her skin
became more supple. Infliximab was stopped after eight infusions.
Now, 4 months later, the previous ulcerations remain healed, no new
digital lesions occurred and the inflammatory parameters are stable.
Conclusion We present a patient with scleroderma (CREST) and
refractory skin lesions. Infliximab combined with MTX was well toler-
ated and effective in the healing of ulcerative lesions.
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reduce serum vascular endothelial growth factor
(VEGF) levels in patients with rheumatoid arthritis: 
a pilot study
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Background Pannus growth in rheumatoid arthritis (RA) is critically
dependent upon accompanying neovascularization. Vascular endothelial
growth factor (VEGF) is a potent angiogenic promoter, which is thought to
play a crucial role in synovial angiogenesis in rheumatoid arthritis (RA).
Serum VEGF levels are elevated in RA patients, and therapy with the anti-
TNF-α antibody infliximab reduces serum VEGF levels in these patients.
Objective The study was conducted to compare the early effect of oral
glucocorticoids (GC) with anti-TNF-α therapy (infliximab) on serum
VEGF levels in patients with RA.
Methods Five RA patients (5/8) who had no prior treatment with
DMARDs or glucocorticoids (GC) were administered 20 mg/day pred-
nisolone. Three patients who failed more than one disease-modifying
antirheumatic drug (DMARD) therapy received infusion with infliximab
(200 mg). VEGF serum levels were measured using ELISA before
treatment and at day 10 or 13 during prednisolone therapy or 14 days
after the first infliximab infusion.
Results Serum VEGF levels in therapy naïve RA patients (GC group)
were higher than those in pretreated patients who received infliximab
(median serum VEGF level: 1106 pg/ml versus 320 pg/ml; P = 0,09).
Treatment with infliximab as well as glucocorticoids significantly
decreased serum VEGF levels after 10–14 days in RA patients (median
serum VEGF level after treatment: GC group 559 pg/ml, infliximab
group 92 pg/ml; P = 0.01 versus without treatment or preinfusion).
Conclusions Treatment with oral glucocorticoids leads to an early and
drastic reduction in serum VEGF levels in therapy naïve RA patients.
TNF-α inhibition by infliximab could reduce low serum VEGF levels in
pretreated RA patients independent of the initial serum VEGF concen-
tration. This is the first report comparing the effect of both therapies on
serum VEGF levels, indicating a possible therapeutic inhibition of
angiogenesis in RA.
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Objective Allogeneic bone marrow transplantation (BMT) may be more
effective than autologous BMT as a treatment for patients with severe
autoimmune diseases, such as rheumatoid arthritis (RA). However, the
application of allogeneic BMT for treatment of RA is not yet feasible
because of the high-dose immunosuppression that is used before and
after BMT. Therefore, in this study collagen-induced arthritis (CIA) – the
classic mouse model for RA – was used to compare the effects of allo-
geneic and syngeneic BMT after less toxic, nonlethal (i.e. nonmyeloabla-
tive) conditioning regimens on established disease in DBA/1 (H-2q) mice.
Methods We induced arthritis in normal DBA/1 (H-2q) mice by immu-
nization with type II collagen (CII) in complete Freund’s adjuvans (CFA).
To allow engraftment, we made use of anti-CD40 ligand monoclonal anti-
body (one injection of 0.5 mg ip) and nonlethal total body irradiation (TBI)
of 6.0 Gy before BMT with 1.0 × 10e7 total BM cells from syngeneic
DBA/1 (H-2q) mice or from fully MHC-mismatched allogeneic BALB/c
(H-2d) mice. After treatment, mice were scored for clinical arthritis, and
serum was taken to measure the amounts of CII-specific antibodies.
Results We were able to induce stable and long-term (>300 days)
donor chimerism (>95%) after transplantation with fully MHC-mis-
matched total BM cells from allogeneic BALB/c (H-2d) mice using a
nonmyeloablative conditioning regimen. After initial exarcebation of
arthritis shortly after allogeneic BMT, due to a graft-versus-host
(GvH)/host-versus-graft (HvG) response, mice receiving allogeneic BM
cells showed a significant suppression of arthritis and CII-specific anti-
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bodies. Syngeneic BMT was also effective in suppressing clinical
disease, although no effects on CII-specific antibodies could be
observed.
Conclusion These data indicate that nonmyeloablative conditioning
using low-dose TBI and anti-CD40 ligand monoclonal antibody fol-
lowed by MHC mismatched allogeneic BMT results in donor
chimerism, disappearence of pathogeneic autoantibodies and improve-
ment in disease activity.
Miscellaneous
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Cross-reaction between the major epitope of Ro60
protein (pep216-232) and a homologous peptide of
Coxsackievirus 3C protease
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Background Coxsackievirus RNA has recently been detected in
biopsy specimens of minor salivary glands from patients with Sjögren’s
syndrome (SS). A peptide of 3C protease of Coxsackievirus (pepCoxs)
has 87% homology with a major linear B-cell epitope of Ro60 protein
spanning the sequence 216–232aa.
Objective To investigate a possible cross-reaction between Coxsack-
ievirus 3C protease and Ro60 autoantigen.
Methods PepCoxs MVTSTITEKLLKNLVKI and pep216-232 of Ro60
KALSVETEKLLKYLEAV were prepared. Sera from 27 patients with SS
and 28 patients with systemic lupus erythematosus (SLE) were tested
against the two homologous peptides. Twenty-eight samples were a-
Ro (+), and 26 samples were a-Ro/a-La (+). Sera from 27 healthy indi-
viduals were used as normal controls. Antibodies against Ro60 peptide
were purified and tested for antipeptide reactivity.
Results Of SLE sera 25%, and 33.3% of SS sera reacted against
pep216-232, whereas 28% of SLE sera and 37% of SS sera reacted
against pepCoxs. The reactivity of normal sera against pep216-232
and pepCoxs was 17.4% and 3.7%, respectively. Pep216-232 was
recognized by 17% of the a-Ro (+) sera and by 42% of the a-Ro/La (+)
sera, whereas pepCoxs was recognized by 28.5% and 38% of the a-
Ro (+) and a-Ro/La (+) sera, respectively. Both peptides reacted more
prominently with a-Ro/La (+) sera from SS patients. Purified a-Ro60
antibodies reacted with both peptides and inhibition experiments
revealed the specificity of this reaction.
Conclusion These results revealed a possible cross-reaction between
the major linear B-cell epitope of Ro60 protein (216–232aa) and the
homologous peptide of Coxsackie virus 3C-protease in SS patients.
This cross-reaction might potentially play a role on autoantibody forma-
tion and pathogenesis of SS.
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Background HDJ2 is among approximately 98 human DnaJ homologues
listed in protein databases. DnaJ homologues cooperate with HSP70
chaperones, which regulate protein conformation under stress as well as
normal physiological conditions. Functions of the HSP70 chaperone
machinery include destruction and repair of misfolded proteins. We previ-
ously observed that several DnaJ homologs are differentially expressed in
synovial tissue of patients with rheumatoid arthritis (RA).
Objective HDJ2 is one of the few DnaJ homologues that can be
detected specifically as protein and mRNA. We therefore wished to
evaluate its expression on both levels in material derived from RA
patients or healthy donors (HD).
Methods Synovial tissue (ST) from RA patients and appropriate con-
trols was stained with a specific monoclonal antibody (immunohisto-
chemistry). The expression of HDJ2 was characterized in peripheral
blood (PB) mononuclear cells (MNC) from HD; PBMNC from RA
patients; and MNC from synovial fluid (SFMNC) and ST from RA
patients. PB and SF leukocytes isolated by density gradient centrifuga-
tion were separated in monocytes (MC), remaining mononuclear cells
(nonMC) and granulocytes. Cell populations were analyzed for HDJ2
expression by FACS and RT-PCR.
Results HDJ2 mRNA was expressed in PBMNC of HD. Separation of
PBMNC in MC and nonMC showed HDJ2 mRNA in both populations.
HDJ2 protein was detected intracellularly in PBMNC of HD by FACS
analysis, with stronger signals in MC than in nonMC. PBMNC derived
from HD and RA patients did not show any surface expression of HDJ2.
PB and SF leukocytes from RA patients varied in their HDJ2 mRNA
expression between presence and absence. HDJ2 protein was overex-
pressed in RA ST and detected on the cell surface of RA SFMNC.
Conclusions HDJ2 mRNA and protein expression are regulated differ-
entially. More patients must be analyzed to describe possible correla-
tions between expression patterns and other parameters and to
understand the function of synovial HDJ2 expression.
Acknowledgement Supported by DFG grant Me 604/6.
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Effects of anti-rheumatic treatments on expression of
microsomal prostaglandin E synthase-1 in
rheumatoid arthritis synovium
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Background mPGES-1 catalyzes the formation of PGE2 from COX-
derived PGH2. mPGES-1 is induced by proinflammatory cytokines and
linked to conditions with high PGE2 biosynthesis. Recent studies in
animals suggest that mPGES-1 upregulation is involved in the pathogen-
esis of inflammatory arthritis, and thus has important clinical relevance for
a better understanding and treatment of rheumatoid arthritis (RA).
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Figure
Allogeneic BMT can suppress both clinical disease and pathogeneic
antibodies. (a) Clinical disease over time. (b) Anti-type II collagen
antibodies are decreased after treatment.S33
Objective Our aim was to study the effects of different antirheumatic
therapies on expression of mPGES-1 in RA synovial tissue.
Methods Synovial biopsies were taken by arthroscopy in patients with
RA before and after TNF-blocking therapy with either etanercept (eight
patients) or infliximab (10 patients), and in patients with chronic inflam-
matory arthritis before and after intra-articular injection of steroids
(16 patients). Immunohistological analysis was performed using anti-
body against mPGES-1 and COX-2. Double immunofluorescence
(DIF) was performed with antibodies to CD3, CD20, CD68, CD163
and prolyne-4-hydroxylase.
Results mPGES-1 staining was detected in synovial lining cells, in sub-
lining scattered cells in all patients, and in endothelial cells in few
patients. DIF showed that mPGES-1 is produced in synovial
macrophages and fibroblasts, whereas in lymphocytes mPGES-1 expres-
sion was not observed. TNF-blocking therapy has heterogeneous effects
on the expression of mPGES-1, as well as COX-2 in synovial tissues.
Intra-articular steroid treatment significantly reduced both mPGES-1 and
COX-2 expression in synovial tissues (P < 0.05); however, the downreg-
ulation of mPGES-1 appears to be more prominent than that of COX-2.
Conclusion The results demonstrate that corticosteroids but not TNF
blockade downregulate mPGES-1. These data might be of importance
for interpretation of effects of various therapies and provide support to
the use of combination of TNF-blockade, corticosteroids, and nons-
teroidal anti-inflammatory drugs.
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Salivary gland epithelial cells (SGEC) express a novel
alternate transcript of the B7.2 costimulatory
molecule that lacks the CD28/CTLA4-binding IgV-like
domain
EK Kapsogeorgou, HM Moutsopoulos, MN Manoussakis
Department of Pathophysiology, National University of Athens, Greece
Arthritis Res Ther 2004 6(Suppl 1):99 (DOI 10.1186/ar1141)
Background Epithelial cells appear to have a central role in the patho-
genesis of Sjögren’s syndrome (SS), by acting as antigen-presenting
cells. SGEC lines established from minor SG biopsies of SS patients
express MHC and B7 costimulatory molecules. We previously showed
that B7.2 molecules expressed by SGEC display distinctive binding
properties denoted by the functional interaction with CD28 receptor
and reduced binding to the negative immune regulator CTLA4.
Objective and Methods To delineate the role of RNA modifications in
the SGEC–B7.2 protein binding properties, we applied a RT-PCR pro-
tocol that amplifies the entire coding region of the B7.2 mRNA. The
amplified PCR products were sequenced and characterized.
Results SGEC were found to express three distinct alternate tran-
scripts of the B7.2 molecule. These included the two previously
described transcripts (encoding the full-length and the soluble form,
respectively), as well as a third novel form (designated as B7.2C).
B7.2C is characterized by exon 4 deletion, which encodes the IgV-like
binding domain of the B7.2 protein to the CD28 and CTLA4 receptors.
The conservation of the signaling peptide and the transmembrane
region in the B7.2C transcript suggests the membranous expression of
the encoded protein. The cell surface expression of the B7.2C protein
was verified in CHO cell lines transfected with this transcript. B7.2C
mRNA analysis of peripheral blood cell subpopulations (monocytes, T
and B cells) revealed exclusive expression by monocytes.
Conclusion The role of B7.2C transcript remains to be determined.
The clustering of B7.2 molecules and the development of a network
has been considered necessary for their effective interaction with
CD28/CTLA4 receptors. Thus, the co-expression of the full length
B7.2 with the truncated B7.2C protein (that lacks the CD28/CTLA4-
binding sites) may lead to negative regulation of T cell activation by
interference of B7.2C in the formation of B7.2 clusters.
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Background HMG-Co A reductase inhibitors (statins) are widely used
lipid-lowering agents. It has recently been shown that, in addition to
their well known effect on cholesterol levels, statins display anti-inflam-
matory activities both in vitro and in vivo. In this context, in vivo prophy-
lactic and therapeutic effects of simvastatin were recently described in
mouse collagen-induced arthritis, a well-described experimental model
for human rheumatoid arthritis (RA).
Objective and Methods The aim of this study was to investigate further
the in vivo effects of three different statins – atorvastatin, rosuvastatin and
simvastatin – using the same experimental model. Different doses and
routes of administration were used for the various statins in an attempt to
elicit antiarthritic activity in preventive and curative treatment protocols.
Results Atorvastatin and rosuvastatin had no in vivo efficacy, as indi-
cated by clinical, histological (synovial hyperplasia, exsudate and carti-
lage damage), immunological (anti-type II collagen IgG production and
T lymphocyte proliferation) and biochemical (IL-6, serum amyloid A and
glucocorticoid production) parameters of inflammation and autoimmu-
nity. The previously described antiarthritic effects of intraperitoneal sim-
vastatin administration were reproduced in our experiments, but could
be accounted for by very severe side effects of the treatment leading to
increased glucocorticoid levels.
Conclusions This work shows that statins do not have any effect in a
murine model of arthritis; this is an unexpected observation, given the
previously described therapeutic effect of statins in immune-mediated
inflammatory diseases. It is still unclear whether statins might have a
benefit in rheumatic diseases.
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Background Myeloid related protein (MRP)8 and MRP14 are released
by early monocytes upon contact with activated endothelium and corre-
late with inflammation in rheumatoid arthritis (RA) and juvenile arthritis.
Objective The aim of the study was to investigate serum
MRP8/MRP14 as biomarker for inflammation in chronic arthritis.
Methods The study included 40 RA patients with active joint involve-
ment (SJC = 14, CRP = 2.4 mg/dl, ESR = 28 mm/hour); 30 SpA
patients with peripheral synovitis (SJC = 2, CRP = 2.2 mg/dl,
ESR = 21 mm/hour); 10 AS patients with exclusive axial involvement
(SJC = 0, CRP = 3.1 mg/dl, ESR = 19 mm/hour); and 20 healthy con-
trols (HC). In 20 RA, 10 peripheral SpA and 10 axial AS patients, sera
were also obtained after 6 weeks of infliximab therapy. Serum
MRP8/MRP14 was measured by ELISA.
Results MRP8/MRP14 was increased in RA (1075 ng/ml; P < 0.001),
peripheral SpA (815 ng/ml; P < 0.001) and axial AS (710 ng/ml;
P < 0.001), as compared with HC (280 ng/ml). In patients with periph-
eral synovitis, MRP8/MRP14 correlated with CRP (RA, r = 0.77,
P < 0.001; peripheral SpA, r = 0.69, P < 0.001) and ESR (RA, r = 0.70,
P < 0.001; peripheral SpA, r = 0.62,  P = 0.001). MRP8/MRP14
decreased after infliximab in RA (P < 0.001), peripheral SpA
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(P = 0.009) and axial AS (P = 0.012). Of 9/40 RA, 6/30 peripheral
SpA and 1/10 axial AS patients with CRP < 1 mg/dl, only one periph-
eral SpA patient had increased MRP8/MRP14 (> mean MRP8/MRP14
in HC + 2SD). Of 17/40 RA, 12/30 peripheral SpA and 6 axial AS
patients with ESR < 20 mm/hour, 3/17 RA, 6/12 peripheral SpA and
3/6 axial AS patients had raised MRP8/MRP14. Finally, we assessed
the sensitivity to change after infliximab. In RA and peripheral SpA,
changes in MRP8/MRP14 were not different from changes in CRP and
ESR, whereas in axial AS changes in MRP8/MRP14 were less pro-
nounced than changes in ESR (P = 0.005).
Conclusion Raised MRP8/MRP14 levels, correlations with CRP and
ESR, and decrease after infliximab confirm that serum MRP8/MRP14
reflect inflammation. Further research is warranted to assess the added
value of MRP8/MRP14 as compared with CRP and ESR.
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Three-dimensional power Doppler sonographic
visualization of synovial vasculature: an ‘in vivo’
model to study angiogenesis in rheumatoid arthritis
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Background Joint damage in rheumatoid arthritis (RA) is caused by a
tumor-like proliferation of synovial cells, which is accompanied by an
increase in vasculature (angiogenesis) to support the metabolic
requirements. Technological improvements such as three-dimensional
(3D) power Doppler sonography have made possible the assessment
of a whole blood vessel tree in a region of interest (ROI).
Objective Because 3D power Doppler sonography plays an important
role in obstetrics and oncology for assessing the vascular system, we
used it to visualize intra-articular synovial new blood vessel formation in
painful and swollen joints of patients with RA.
Methods Inflamed wrist, knee or finger joints in 21 patients with active
RA were investigated by ultrasound. Vascularity near and inside the
joint capsule was visualized by power Doppler mode. The online 3D
power Doppler function, provided by the ATL/HDI 5000 vascular soft-
ware, was used to generate a 3D image of the periarticular and intra-
articular blood vessels.
Results In 21 patients with RA who showed power Doppler signals in
2D mode, the 3D function revealed a blood vessel tree branching out
from periarticular small blood vessels into the joint capsule. Until now it
was possible to obtain good 3D imaging of synovial vasculature in the
wrist (15 patients), knee (three patients), and finger joints (MCP II and
PIP III) (three patients).
Conclusion This is the first report on 3D power Doppler imaging of syn-
ovial angiogenesis. In comparison with 2D power Doppler, 3D mode
reveals more and very small blood vessels in connection with the whole
blood vessel tree, and provides a new opportunity to study the architec-
ture and morphological structure of synovial vasculature in various joint
disorders and under different conditions. Thus 3D power Doppler
sonography may be used as an ‘in vivo’ model to study the mechanisms
between inflammation and angiogenesis in rheumatoid joint damage.
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Background Joint destruction in rheumatoid arthritis (RA) is caused by
hypervascularized pannus which invades cartilage and bone. Angio-
genesis is recognized as a key event in the formation and maintenance
of the pannus, which is regulated by a delicate balance of angiogenesis
inducers, including vascular endothelial growth factor (VEGF), and dif-
ferent angiostatic agents. Technological improvements such as high-
resolution ultrasound and power Doppler mode make the discrimination
between periarticular and intra-articular blood flow possible.
Objective We used power Doppler sonography to visualize intra-articu-
lar new blood vessel formation as a result of angiogenesis to evaluate a
possible correlation with serum VEGF levels.
Methods  Vascularity near and inside the wrist of 23 RA patients and
12 healthy controls was visualized by power Doppler sonography.
Microvascular doppler flow was localized to either inside or outside the joint
capsule, and estimated according to a grading from 1 to 4. Serum levels of
VEGF were measured using a standard quantitative sandwich ELISA.
Results Power Doppler mode identified increased synovial microvas-
cular blood flow inside the joint capsule in 20 RA patients (87%), in
comparison with in none of the healthy controls (P < 0.0001). Although
the median serum VEGF level in RA patients (853 pg/ml) was higher
than in healthy controls (638 pg/ml), qualitative Doppler sonographic
estimation of the intensity of intra-articular synovial blood flow did not
correlate with the actual serum VEGF level of the same patient.
Conclusion Power Doppler sonography is a reliable imaging modality
to detect increased intra-articular synovial microvascular blood flow as
a result of vasodilatation and new blood vessel formation (angiogene-
sis) in acute arthritis of RA patients. A correlation with elevated serum
VEGF levels indicates this method as a helpful tool to study the role of
blood vessels in the rheumatoid inflammatory process.
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Impaired clearance of apoptotic cell material has been implicated in the
pathogenesis of systemic lupus erythematosus (SLE). We analyzed the
phagocytotic potency of macrophages differentiated from CD34-positive
stem cells derived from the peripheral blood from SLE patients and normal
healthy donors (NHD), respectively. Furthermore, we examined the uptake
of beads and dying cells by granulocytes of SLE patients and NHD.
We found that, in a subgroup of SLE patients, the proliferation and dif-
ferentiation patterns of the stem cells were different in comparison with
NHD. Furthermore, in SLE patients a significantly reduced number of
macrophages differentiated out of the stem cells. Additionally, the
uptake capacity of some macrophages of SLE patients was reduced in
comparison with NHD. Regarding the phagocytosis of albumin beads,
polyglobuline beads, apoptotic and necrotic cells as well as degraded
chromatin, we found that macrophages and/or granulocytes of some
SLE patients showed a strongly reduced uptake of the prey.
The defective clearance of dying cells in a subgroup of SLE patients
seems to be an intrinsic defect because fewer macrophages differenti-
ated out of stem cells, and some of the generated phagocytes also
showed reduced uptake efficiency. Furthermore, the impaired clear-
ance capacities of granulocytes from some SLE patients could play an
important role in the development of autoimmunity.
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Background Anti-SL (Ki) antibody was described in 1981 in patients
affected by systemic lupus erythematosus (SLE) and sicca symptoms.
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Objective To evaluate clinical and serological profile associated with
anti-SL antibodies
Methods Twenty-six consecutive sera with anti-Sl antibodies, selected
from our laboratory routine ENA detection, were studied. All sera were
analyzed by counter immunoelectrophoresis (CIE) for anti-ENA detec-
tion, using rabbit thymus and human spleen extract as substrates. ANA
(by IFI assay on HEp-2 cells), anti-dsDNA (by Farr assay), anti-ENA,
anticardiolipin (aCL) and anti-beta2GPI (by ELISA) were detected at
disease onset and during follow up. The patients (20 female and 6
male) had a mean age at onset of 39.4 years (SD: 18.3 years) and a
mean follow-up of 10.7 years (SD: 7.3 years).
Results All the patients were affected by autoimmune rheumatic dis-
eases, but one with HCV-related cryoglobulinemia. SLE and primary
Sjögren Syndrome (pSS) were the most frequent diagnoses achieved
(in 13 and in 6 cases, respectively). Main clinical features were repre-
sented by skin involvement (65%), Raynaud’s phenomenon (38%),
xerophtalmia (54%), xerostomia (34%) and serositis (15%). Neverthe-
less, severe manifestations of disease were frequently observed: CNS
involvement in three (11.5%) and renal disease in four cases (15%),
while one patient with SLE had primary pulmonary hypertension. No
cases of hemolytic anemia or severe cytopenia were recorded. ANA
positivity was observed in all the sera. Anti-SL antibodies were
detected as isolated antibody specificity in only five patients, while nine
sera showed reactivity to anti-SL plus one antinuclear specificity (5
anti-dsDNA, 2 anti-Ro, one anti-RNP, one anti-Sm). Ten patients had
anti-SL antibodies associated with two other ANA specificities: in five
cases, anti-Ro and anti-dsDNA; in three, anti-Ro and anti-La; in two
cases, anti-Sm and anti-dsDNA. Two patients showed multiple antinu-
clear specificities (anti-SL with anti-Ro, anti-La and anti-dsDNA in one
case and anti-SL with anti-Ro, anti-Ku and anti-dsDNA in another). Anti-
cardiolipin and anti-beta2GPI were detected in seven and four patients,
respectively.
Conclusion Anti-SL antibodies identify a group of patients mainly
affected by SLE and pSS, presenting in approximately one third of
patients a severe disease with pulmonary, CNS or kidney involvement.
Twenty-one patients with anti-SL (81%) have multiple antinuclear
specificities.
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Background Rheumatoid arthritis (RA) synovial fibroblasts destruc-
tively invade into joint cartilage. We could demonstrate in our pannus
model of interactive three-dimensional tissue culture that the immortal-
ized synovial fibroblast cells from a normal donor (K4IM) and a patient
with RA (HSE) provide an in vitro system for differential invasiveness
into artificial cartilage.
Objective In this study, we investigated the molecular differences
between these two cell lines and the influence of antirheumatic drugs
on their expression profiles to gain insight into molecular pathways of
joint destruction.
Methods HSE and K4IM cells were characterized by immunostaining
with Fibroblast-AK, CD3, CD31, CD68 and MAC3 antibodies. MTS-
assay provided information for kinetics and effective concentration of
MTX, decortin and diclofenac. Gene expression profiles were gener-
ated with HG-U133A Affymertrix GeneChips, analyzed by RMA, dCHIP
and MAS5.0 software, and validated by RT-PCR, ELISA.
Results Positive fibroblast-AK staining confirmed the fibroblastoid phe-
notype of both cell lines. RA fibroblasts reacted more sensitively
towards MTX-mediated cytotoxicity compared to K4IM fibroblasts.
Gene expression profiling revealed 1303 differentially expressed genes
between HSE and K4IM. MTX affected 191/1365, Decortin 84/172
and Diclofenac 19/0 genes in HSE/K4IM, respectively, as identified by
all three softwares in common. Only 41, 26, or 8 genes were influ-
enced in HSE towards the K4IM profile by MTX, Decortin or
Diclofenac, respectively. Regulation of ten selected genes was con-
firmed by RT-PCR. Proteins in the supernatant from three of four genes
revealed similar ratios by ELISA compared to transcription levels.
Conclusion Only a minority of differentially regulated genes in the RA
fibroblasts was positively influenced by current therapeutics. Those
genes, which were not influenced, may be new potential candidates for
therapeutic intervention.
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